Page last updated: 2024-11-10

daidzein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281708
CHEMBL ID8145
CHEBI ID28197
SCHEMBL ID19814
MeSH IDM0045889

Synonyms (199)

Synonym
BIDD:ER0120
AC-6035
S00273
4',7-dihydroxy-iso-flavone
7-hydroxy-3-(4-hydroxy-phenyl)-chromone
AKOS002385052
HMS3267J04
BB 0259520
AB00052712-08
BRD-K42095107-001-05-6
BRD-K42095107-001-02-3
gtpl2828
7,4'-dihydroxyisoflavone
7-hydroxy-3-(4-hydroxyphenyl)-4h-chromen-4-one
4',7-dihydroxyisoflavone
CHEBI:28197 ,
7-hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone
daidzeol
7-hydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
DIVK1C_001023
KBIO1_001023
SDCCGMLS-0066422.P001
k 251b
einecs 207-635-4
isoflavone, 4',7-dihydroxy-
ccris 7600
brn 0231523
EU-0100412
daidzein, >=98%, synthetic
SPECTRUM_000255
SPECTRUM4_001964
c15h10o4
NCGC00015365-01
NCGC00025156-01
lopac-d-7802
tocris-1417
BIOMOLKI2_000066
NCGC00025156-10
diadzein
ACON0_001477
SMP1_000089
IDI1_001023
MEGXM0_000123
BSPBIO_001741
SPECTRUM5_000857
LOPAC0_000412
NCGC00025156-02
UPCMLD-DP052:001
npi-031e
k-251b
486-66-8
daidzein ,
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
4h-1-benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-
smr000326832
MLS000859973
UPCMLD-DP052
NCGC00025156-07
NCGC00025156-09
NCGC00025156-04
NCGC00025156-05
KBIO2_003303
KBIO3_001241
KBIOSS_000735
KBIO2_000735
KBIOGR_002432
KBIO2_005871
SPBIO_000205
NINDS_001023
SPECTRUM2_000053
SPECTRUM3_000191
SPECTRUM200789
BIOMOLKI_000060
daidzein (4',7-dihydroxyisoflavone)
OPREA1_305345
OPREA1_182317
ACON1_000543
NCGC00025156-06
NCGC00168978-01
chembl8145 ,
NCGC00025156-03
bdbm23420
MLS001304056
NCGC00025156-08
NCGC00168978-02
7,4'-dihydroxy-isoflavone (3a)
us8552057, 7
NCGC00015365-04
D 7802
80E3ED75-D852-4D97-9BD6-B5ADE7EA25A1
NCGC00015365-14
4,7-dihydroxyisoflavone
BMK1-F12
HMS503M07
FT-0665448
FT-0665449
D2668
HMS1922P18
LMPK12050038
STK801626
HMS3261C06
npi 031e
unii-6287wc5j2l
6287wc5j2l ,
5-18-04-00089 (beilstein handbook reference)
cas-486-66-8
dtxcid102310
dtxsid9022310 ,
NCGC00257367-01
tox21_303650
tox21_201444
NCGC00258995-01
BBL010490
HMS2233H24
CCG-38357
NCGC00015365-15
NCGC00015365-06
NCGC00015365-02
NCGC00015365-13
NCGC00015365-08
NCGC00015365-12
NCGC00015365-17
NCGC00015365-11
NCGC00015365-05
NCGC00015365-16
NCGC00015365-03
NCGC00015365-09
NCGC00015365-07
NCGC00015365-10
FT-0603419
NCGC00015365-18
LP00412
S1849
HMS3370C03
HY-N0019
d-(+)-alpha-methylbenzylamine
4',7-dihydroxy isoflavone
7-hydroxy-3-(4-hydroxyphenyl)-chromen-4-one
d-(+)-alpha-methylbenzyl amine
SCHEMBL19814
KS-5260
daidzein (constituent of astragalus) [dsc]
daidzein [usp-rs]
daidzein [mi]
daidzein [mart.]
daidzein (constituent of soy isoflavones) [dsc]
daidzein [who-dd]
daidzein (constituent of red clover) [dsc]
daidzein [inci]
tox21_500412
NCGC00261097-01
MLS006011853
Q-200924
HMS3468L18
daidzein, pharmaceutical secondary standard; certified reference material
HB2488
7-hydroxy-3-(4-hydroxyphenyl)-4h-1- benzopyran-4-one
HMS3649B20
AB00052712_10
mfcd00016954
daidzein, united states pharmacopeia (usp) reference standard
daidzein, purum, >=98.0% (tlc)
daidzein, analytical standard
daidzein, primary pharmaceutical reference standard
HMS3655A18
4',7-dihydroxy-isoflavone
SR-01000075492-8
SR-01000075492-3
sr-01000075492
SR-01000075492-1
SR-01000075492-7
SW218107-2
daidzein (dai)
Q408732
HMS3676O12
DB13182
daidzein,(s)
7-hydroxy-3-(4-hydroxyphenyl)-4h-
SR-01000075492-12
BCP28286
7-hydroxy-3-(4-hydroxy-phenyl)-chromen-4-one
HMS3412O12
AMY25222
BRD-K42095107-001-08-0
SDCCGSBI-0050397.P003
NCGC00015365-31
SY049259
zf1 ,
daidzein-3,5,8-d3
EN300-116213
HY-N0019R
CS-0694988
daidzein (standard)
Z1494829514
daidzein (constituent of soy isoflavones)
daidzein (constituent of astragalus)
daidzein (constituent of red clover)
daidzein (usp-rs)
daidzein (mart.)

Research Excerpts

Overview

Daidzein is a phytoestrogen isoflavone found in soybeans and other legumes. It has anti-inflammation, anti-allergy, and anti-aging effects.

ExcerptReferenceRelevance
"Daidzein (1) is a natural estrogenic isoflavone. "( Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
Bhatnagar, D; Boue, SM; Burow, ME; Collins-Burow, BM; Driver, J; Elliott, S; Jiang, Q; McLachlan, JA; Payton-Stewart, F; Rhodes, LV; Sridhar, J; Stevens, C; Wang, G; Wiese, TE; Zhang, Q; Zheng, S, 2010
)
2.03
"Daidzein is a phytoestrogen isoflavone found in soybeans and other legumes. "( Therapeutic Potential of Isoflavones with an Emphasis on Daidzein.
Akram, M; Alshehri, MM; Cho, WC; Cruz-Martins, N; Daştan, SD; Herrera-Bravo, J; Iqbal, M; Jara, EL; Kregiel, D; Kumar, M; Martorell, M; Ozdemir, FA; Pons, DG; Salazar, LA; Sharifi-Rad, J; Torrens-Mas, M; Uprety, Y, 2021
)
2.31
"Daidzein is an isoflavone that has been used for the treatment of CVDs."( Daidzein suppresses TGF-β1-induced cardiac fibroblast activation via the TGF-β1/SMAD2/3 signaling pathway.
Chen, L; Hu, L; Huang, K; Liang, M; Shu, J; Wang, Z; Wu, Y, 2022
)
2.89
"Daidzein (DZ) is an isoflavone compound extracted from soy plants and has been shown to possess many medicinal benefits."( Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity.
Chang, YC; Chen, MC; Chen, RJ; Huang, CY; Kuo, CH; Kuo, WW; Mhone, TG; Shih, TC; Wang, TF; Yeh, CM, 2022
)
2.89
"Daidzein (DAI) is a classical isoflavonic phytoestrogen with specific oestrogenic activity."( Daidzein supplementation improved fecundity in sows via modulation of ovarian oxidative stress and inflammation.
Chen, D; He, G; He, J; Huang, Z; Li, H; Li, Y; Luo, J; Luo, Y; Mao, X; Xie, K; Yan, H; Yu, B; Yu, J; Zhao, X; Zheng, P, 2022
)
2.89
"Daidzein is a dietary isoflavone that has various biological activities."( Modulation of inflammatory, oxidative, and apoptotic stresses mediates the renoprotective effect of daidzein against glycerol-induced acute kidney injury in rats.
Abdel Moneim, AE; Al-Amer, OM; Al-Ghamdy, AO; Albarakati, AJA; Albrakati, A; Alharthi, F; Alsharif, KF; Althagafi, HA; Elhefny, MA; Elhenawy, AA; Elmahallawy, EK; Habotta, OA; Hassan, KE; Hawsawi, YM; Kassab, RB; Lokman, MS; Moustafa, AA; Oyouni, AAA, 2023
)
1.85
"Daidzein is a common isoflavone, having multiple biological effects such as anti-inflammation, anti-allergy, and anti-aging. "( Synthesis of Daidzein Glycosides, α-Tocopherol Glycosides, Hesperetin Glycosides by Bioconversion and Their Potential for Anti-Allergic Functional-Foods and Cosmetics.
Fujitaka, Y; Hamada, H; Iwaki, T; Kiriake, Y; Kuboki, A; Saikawa, T; Shimoda, K; Uesugi, D, 2019
)
2.33
"Daidzein (DA) is a kind of isoflavone that is extracted primarily from soy plants and that has become increasingly popular as a dietary supplement. "( Transcriptome sequencing reveals genetic mechanisms of reproduction performance stimulated by dietary daidzein in laying breeder hens.
Hu, Y; Shao, D; Shi, S; Tong, H; Wang, Q, 2020
)
2.22
"Daidzein (DAI) is a kind of natural isoflavonic phytoestrogen with estrogenic activity. "( Daidzein supplementation enhances embryo survival by improving hormones, antioxidant capacity, and metabolic profiles of amniotic fluid in sows.
Chen, D; He, J; Huang, Z; Li, Y; Luo, J; Luo, Y; Mao, X; Xie, K; Yan, H; Yu, B; Yu, J; Zheng, P, 2020
)
3.44
"Daidzein (DA) is an isoflavone that is primarily extracted from soy plants. "( Transcriptomics-Related Mechanisms of Supplementing Laying Broiler Breeder Hens with Dietary Daidzein to Improve the Immune Function and Growth Performance of Offspring.
Fan, H; Gan, L; Guo, Y; Lv, Z, 2018
)
2.14
"Daidzein is an important flavonoid and has been shown to exhibit a diversity of pharmacological properties, including antimicrobial and anticancer activities."( Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade.
Chen, XG; Hua, F; Li, CH; Liu, XP, 2018
)
2.64
"Daidzein (C15H10O4) is a type of isoflavone. "( Conformational analysis and vibrational study of daidzein by using FT-IR and FT-Raman spectroscopies and DFT calculations.
Bharti, P; Kumar, S; Maurya, R; Singh, H; Singh, S; Srivastava, A; Tandon, P, 2014
)
2.1
"Daidzein is a major component of isoflavones, and its hydroxylated forms are valuable phytochemicals with anti-cancer and anti-oxidant activity. "( Regioselectivity-driven evolution of CYP102D1 for improved synthesis of 3'-ortho-dihydroxyisoflavone.
Choi, KY; Kim, BG; Yang, YH, 2015
)
1.86
"Daidzein is an isoflavone derived from soybeans that exerts preventive effects on bone loss in ovariectomized (OVX) animals. "( Kanamycin inhibits daidzein metabolism and abilities of the metabolites to prevent bone loss in ovariectomized mice.
Fujii, S; Fujioka, M; Ishimi, Y; Katsumata, S; Takeda, K; Uehara, M, 2016
)
2.21
"Daidzein is a major dietary source of isoflavones found in Leguminosae, and belongs to the family of diphenolic compounds. "( Daidzein increases OPG/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells.
Li, L; Li, LZ; Li, ZY; Sun, J; Sun, WJ; Wang, C; Wang, Y; Yu, LR; Zhang, YL; Zhao, Y, 2016
)
3.32
"Daidzein is a very good candidate for treating cardio-cerebrovascular diseases, but its poor oral absorption and bioavailability limit its curative efficacy. "( The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Chen, L; Gao, Y; Gu, W; Li, Y; Xu, Z, 2008
)
2.17
"Daidzein is an abundant isoflavone present in soy. "( Effect of daidzein on anxiety, social behavior and spatial learning in male Balb/cJ mice.
Jia, R; Tai, F; Yuan, A; Zeng, S; Zhai, P; Zhang, X, 2010
)
2.21
"Daidzein is an important isoflavone in soy. "( Maternal exposure to daidzein alters behaviour and oestrogen receptor alpha expression in adult female offspring.
An, X; Song, Z; Tai, F; Wu, R; Yu, C; Zhang, X, 2010
)
2.12
"Daidzein is a potential natural alternative to estradiol during therapy of some malignancies in men. "( Daidzein effects on ACTH cells: immunohistomorphometric and hormonal study in an animal model of the andropause.
Ajdzanovic, VZ; Filipoviç, BR; Milosevic, VLj; Sosic-Jurjevic, BT; Trifunovic, SL, 2011
)
3.25
"Daidzein is a naturally occurring compound and has various health benefits. "( Inhibitory effects of daidzein on intestinal motility in normal and high contractile states.
Chen, D; Lin, Y; Lv, B; Tang, Z; Xiong, Y, 2012
)
2.14
"Daidzein is a soy isoflavone with estrogenic activity present in plant-based food items and health foods and used as an alternative therapy for cancer and cardiovascular diseases. "( Long-term effects of phytoestrogen daidzein on penile cavernosal structures in adult rats.
Cui, Y; Feng, Y; Huang, Y; Jiang, C; Pan, L; Xia, X, 2008
)
2.07
"Daidzein is a natural isoflavone found in Leguminosae. "( Stimulatory effect of Daidzein in osteoblastic MC3T3-E1 cells.
Sugimoto, E; Yamaguchi, M, 2000
)
2.06
"Daidzein is an estrogenic isoflavone present in many plants and therefore consumed in relatively high doses by humans. "( Disposition and biotransformation of the estrogenic isoflavone daidzein in rats.
Bayer, T; Colnot, T; Dekant, W, 2001
)
1.99

Effects

Daidzein has a low affinity for the estrogen receptor (3 orders of magnitude lower than estradiol) It has been demonstrated to have estrogenic effects in rodents after administration of high doses.

Daidzein has a low affinity for the estrogen receptor (3 orders of magnitude lower than estradiol) and has been demonstrated to have estrogenic effects in rodents after administration of high doses. It has anti-inflammatory and antioxidant effects, as well as the dose-dependent inhibition effect on cancer cells.

ExcerptReferenceRelevance
"Daidzein has a wide range of pharmacodynamic properties in the treatment of cancer, neurodegenerative disorders, cardiac disorders, diabetes and its complication, osteoporosis, and skin disorders."( Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone.
Kulkarni, YA; Laddha, AP, 2023
)
1.87
"Daidzein, however, has a superior neuron-protective effect to other isoflavones."( Anti-inflammatory effects of daidzein on primary astroglial cell culture.
Lin, YS; Liu, MH; Sheu, SY; Sun, JS, 2009
)
1.37
"Daidzein has a low affinity for the estrogen receptor (3 orders of magnitude lower than estradiol) and has been demonstrated to have estrogenic effects in rodents after administration of high doses."( Disposition and biotransformation of the estrogenic isoflavone daidzein in rats.
Bayer, T; Colnot, T; Dekant, W, 2001
)
1.27
"Daidzein has several biological effects such as antioxidation, anti-inflammation, chemoprevention, and anticancer effects. The aim of this study was to evaluate the impact of nano-formulations (nanoemulsion-NE and nanosuspension-NS) prepared to increase the oral bioavailability of daidzein, a poorly water-soluble isoflavone, on the pharmacokinetic parameters of daidzein in rats."( Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
Akıllıoğlu, K; Aksu, F; Cetin, M; Demirtürk, E; Dönmez Kutlu, M; Köse, S; Ugur Kaplan, AB, 2022
)
2.43
"Daidzein has been studied by many researchers for its pharmacological activities."( Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone.
Kulkarni, YA; Laddha, AP, 2023
)
1.87
"Daidzein has been reported to be effective in regulating lipid metabolism in animals. "( RNA-Seq analysis reveals the potential molecular mechanisms of daidzein on adipogenesis in subcutaneous adipose tissue of finishing Xianan beef cattle.
Bai, J; Li, M; Liang, H; Liu, C; Ouyang, K; Pan, K; Qi, X; Qu, M; Song, X; Xin, J; Xu, L; Yi, Z; Zhao, X, 2020
)
2.24
"Daidzein has become increasingly popular as a dietary supplement, particularly for postpeak-estrus animals, as a safe and natural alternative estrogen-like compound. "( Safety evaluation of daidzein in laying hens: Effects on laying performance, hatchability, egg quality, clinical blood parameters, and organ development.
Dou, TC; Hu, YP; Li, SM; Lu, J; Qu, L; Shen, MM; Wang, KH, 2017
)
2.22
"Daidzein has garnered interest in its antitumor activity especially in proliferation inhibition."( Daidzein inhibits choriocarcinoma proliferation by arresting cell cycle at G1 phase through suppressing ERK pathway in vitro and in vivo.
An, R; Sun, R; Xue, Y; Yang, L; Zeng, X; Zheng, W, 2017
)
2.62
"Daidzein (DZ) has anti-inflammatory and antioxidant effects, as well as the dose-dependent inhibition effect on cancer cells. "( The cytotoxic and genotoxic effects of daidzein on MIA PaCa-2 human pancreatic carcinoma cells and HT-29 human colon cancer cells.
Cetin, M; Cicek, B; Dodurga, Y; Gundogdu, G; Secme, M, 2020
)
2.27
"Daidzein, however, has a superior neuron-protective effect to other isoflavones."( Anti-inflammatory effects of daidzein on primary astroglial cell culture.
Lin, YS; Liu, MH; Sheu, SY; Sun, JS, 2009
)
1.37
"Daidzein (Daid) has been implicated in bone health for its estrogen-'like' effects but low bioavailability, unfavorable metabolism and uterine estrogenicity impede its clinical potential. "( Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Changkija, B; Chattopadhyay, N; Dixit, M; Jain, GK; Khan, K; Khan, MP; Kumar, A; Lahiri, S; Maurya, R; Nagar, GK; Singh, D; Singh, SP; Srivastava, K; Trivedi, R; Tyagi, AM; Yadav, DK, 2013
)
2.13
"Daidzein has obvious protective effect on drug-induced arrhythmia, which may be related to its inhibition of Na+ or Ca2+ influx and its blocking beta-adrenergic receptor."( [Effect of daidzein on antiarrhythmia].
Lai, F; Qiu, F; Ye, HY; Yiao, XS; Zeng, J, 2003
)
2.15
"Daidzein has antiproliferative effects on human estrogen-receptor-positive and negative pancreatic cancer cells, but their mechanisms may be different."( Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells in vitro.
Dai, DJ; Guo, JM; Liu, Q; Ma, HH; Xiao, BX, 2004
)
2.16
"Daidzein has a low affinity for the estrogen receptor (3 orders of magnitude lower than estradiol) and has been demonstrated to have estrogenic effects in rodents after administration of high doses."( Disposition and biotransformation of the estrogenic isoflavone daidzein in rats.
Bayer, T; Colnot, T; Dekant, W, 2001
)
1.27

Actions

Daidzein exhibits a slower release behavior from PPI than that from PAMAM. It did not increase metastasis to lymph nodes and acted as a radiosensitizer for prostate tumors.

ExcerptReferenceRelevance
"Daidzein can enhance the immunocompetence of late lactation cows and strengthen cow resistance to heat stress."( Daidzein enhances immune function in late lactation cows under heat stress.
Chen, HL; He, SJ; Jin, EH; Li, SH; Liu, DY; Liu, SQ; Tang, YG; Zhong, LT, 2014
)
2.57
"Daidzein did not increase metastasis to lymph nodes and acted as a radiosensitizer for prostate tumors. "( Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy.
Ahmad, Z; Hillman, GG; Sarkar, FH; Singh-Gupta, V; Yunker, CK; Zhang, H; Zwier, D, 2010
)
3.25
"Daidzein exhibits a slower release behavior from PPI than that from PAMAM."( Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities.
Cheng, Y; Ding, L; Shao, N; Su, Y; Wang, Y; Yan, X; Ye, X; Zhang, H; Zhao, C; Zhao, D, 2011
)
1.09

Treatment

Daidzein treatment protected retina from damage in hyperglycaemic conditions. Daidzeins prevented the loss of cardiac marker enzyme from heart tissue and increased level of AMPK and SIRT1 in plasma.

ExcerptReferenceRelevance
"Daidzein-treated animals also showed improvement in voiding efficiency."( Daidzein attenuates urinary bladder dysfunction in streptozotocin-induced diabetes in rats by NOX-4 and RAC-1 inhibition.
Kulkarni, YA; Laddha, AP, 2022
)
2.89
"Daidzein treatment decreased MDA and increased CAT and GSH level in IR+Daidzein group."( Daidzein alleviated the pathologies in intestinal tissue against ischemia-reperfusion.
Aşır, F; Durgun, C, 2023
)
3.07
"Daidzein treatment improved histopathology against intestinal IR."( Daidzein alleviated the pathologies in intestinal tissue against ischemia-reperfusion.
Aşır, F; Durgun, C, 2023
)
3.07
"Daidzein treatment protected retina from damage in hyperglycaemic conditions. "( Daidzein ameliorates diabetic retinopathy in experimental animals.
Kulkarni, YA; Laddha, AP, 2021
)
3.51
"Daidzein treatment was started after six weeks of diabetes induction."( Daidzein mitigates myocardial injury in streptozotocin-induced diabetes in rats.
Kulkarni, YA; Laddha, AP, 2021
)
2.79
"Daidzein treatment prevented the loss of cardiac marker enzyme from heart tissue and also increased the level of AMPK and SIRT1 in plasma."( Daidzein mitigates myocardial injury in streptozotocin-induced diabetes in rats.
Kulkarni, YA; Laddha, AP, 2021
)
2.79
"Daidzein treatment led to significant improvement in intracerebroventricular-streptozotocin (ICV-STZ)-induced memory and learning impairments that was evaluated by Morris water maze test and spontaneous locomotor activity."( Protective effect of daidzein against streptozotocin-induced Alzheimer's disease via improving cognitive dysfunction and oxidative stress in rat model.
Gong, C; Shi, X; Wang, G; Wei, J; Yang, F, 2019
)
1.55
"Daidzein pretreatment for seven days at a dose of 1 mg/kg body weight subcutaneously increased the survival time of septic mice. "( Daidzein pretreatment improves survival in mouse model of sepsis.
Kandasamy, K; Mishra, SK; Narasimha Reddy, ChE; Panigrahi, M; Parida, S; Singh, TU; Singh, V; Thangamalai, R, 2015
)
3.3
"Daidzein pretreatment for 7 d in sepsis increased the survival time in mice, which may be relate to decrease in bacterial load, anti-inflammatory effect, and protection from lung injury."( Daidzein pretreatment improves survival in mouse model of sepsis.
Kandasamy, K; Mishra, SK; Narasimha Reddy, ChE; Panigrahi, M; Parida, S; Singh, TU; Singh, V; Thangamalai, R, 2015
)
3.3
"Daidzein treatment stabilizes BRF2 and BRF1 mRNAs and selectively decreases methylation of the BRF2 promoter."( Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.
Cabarcas-Petroski, S; Diette, N; Koo, J; Petrie, JL; Schramm, L; White, RJ, 2015
)
1.36
"Daidzein treatment resulted in decreases in cyclin D, CDK2, and CDK4, whereas the expression of CDK6 and cyclin E was unchanged."( Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells.
Choi, EJ; Kim, GH, 2008
)
2.51
"Daidzein treatment significantly decreased (p<0.05): volume density of ACTH cells, circulating ACTH and corticosterone by 24%, 48% and 33%, respectively, compared to the Orx group."( Daidzein effects on ACTH cells: immunohistomorphometric and hormonal study in an animal model of the andropause.
Ajdzanovic, VZ; Filipoviç, BR; Milosevic, VLj; Sosic-Jurjevic, BT; Trifunovic, SL, 2011
)
2.53
"Daidzein-treated ducks had higher body weight and oviduct weight compared with their controls."( Effect of daidzein on egg-laying performance in Shaoxing duck breeders during different stages of the egg production cycle.
Chen, J; Chen, WH; Lu, LZ; Ni, YD; Tao, ZR; Zhao, RQ; Zhou, YC, 2005
)
1.45
"RP, daidzein, and daidzin treatment do not significantly affect the body weight and water or food intake of the hamsters."( Daidzin and daidzein suppress free-choice ethanol intake by Syrian golden hamsters.
Keung, WM; Vallee, BL, 1993
)
1.15
"Daidzein treatment significantly increased the birth weight of male piglets and markedly reduced the level of ERbeta mRNA in the hypothalamus, but not in the pituitary."( Feeding daidzein to late pregnant sows influences the estrogen receptor beta and type 1 insulin-like growth factor receptor mRNA expression in newborn piglets.
Chen, J; Ender, K; Kuhn, G; Nürnberg, G; Ren, MQ; Wegner, J, 2001
)
1.47
"Daidzein treatment of hepatoma H4IIE cells increased catalase mRNA expression two- to threefold."( The phytoestrogen daidzein affects the antioxidant enzyme system of rat hepatoma H4IIE cells.
Kahl, R; Ohler, S; Röhrdanz, E; Tran-Thi, QH, 2002
)
1.37
"Treatment with daidzein (10, 25, and 50 µM/ml) to LPS-induced BV2 microglia exhibited significantly (p < 0.05) decreased NO, pro-inflammatory mediators PGE2, IL6, and IlL-1β."( Daidzein exerts neuroprotective activity against MPTP-induced Parkinson's disease in experimental mice and lipopolysaccharide-induced  BV2 microglial cells.
Chen, W; Wang, K; Wang, M; Wang, Y; Wu, Q, 2022
)
2.5
"Treatment with daidzein at dose of 50 and 100 mg/kg significantly reduced the elevated bladder capacity (2.91 ± 0.11 mL, p < 0.01 and 2.65 ± 1.13 mL, p < 0.001) and residual volume (1.40 ± 0.15 mL, p < 0.001 and 1.15 ± 0.05 mL, p < 0.001)."( Daidzein attenuates urinary bladder dysfunction in streptozotocin-induced diabetes in rats by NOX-4 and RAC-1 inhibition.
Kulkarni, YA; Laddha, AP, 2022
)
2.5
"Treatment with daidzein at a dose of 50 and 100 mg/kg significantly reduced the elevated level of blood glucose (p < 0.01 and p < 0.01)."( Daidzein ameliorates diabetic retinopathy in experimental animals.
Kulkarni, YA; Laddha, AP, 2021
)
2.4
"Treatment with daidzein at dose 100 mg/kg significantly normalized the QT interval, PR interval, and R wave amplitude."( Daidzein mitigates myocardial injury in streptozotocin-induced diabetes in rats.
Kulkarni, YA; Laddha, AP, 2021
)
2.4
"Treatment with daidzein for 48 h reduced cell viability in a dose‑dependent manner."( Daidzein induces choriocarcinoma cell apoptosis in a dose-dependent manner via the mitochondrial apoptotic pathway.
An, R; Liu, T; Sun, R; Xue, Y; Yang, L; Zheng, W, 2018
)
2.26
"Co-treatment with daidzein decreased the level of ERβ without significant changing of the GPR30 protein level."( The key involvement of estrogen receptor β and G-protein-coupled receptor 30 in the neuroprotective action of daidzein.
Kajta, M; Krzeptowski, W; Lason, W; Lenartowicz, M; Litwa, E; Rzemieniec, J; Wojtowicz, AK, 2013
)
0.93
"Treatment with daidzein reduced food/caloric intake and body weight gain in obese rats."( Pharmacological administration of the isoflavone daidzein enhances cell proliferation and reduces high fat diet-induced apoptosis and gliosis in the rat hippocampus.
Cifuentes, M; Crespillo, A; de Fonseca, FR; Fernández-Llebrez, P; Grondona, JM; López-Ávalos, MD; Pavón, FJ; Pérez-Martín, M; Rivera, P; Serrano, A; Suárez, J; Vida, M, 2013
)
0.98
"Rats treated with daidzein exhibited fewer deep slips over the course of the experiment than rats which received only vehicle (p<0.05)."( Subcutaneous daidzein administration enhances recovery of skilled ladder rung walking performance following stroke in rats.
Banz, WJ; Cheatwood, JL; Knapp, AN; Stout, JM; Wallace, DG, 2013
)
1.08
"Treatment with daidzein reduced the expression of Matrix metalloproteinase 2 (MMP-2) and increased the expression of Tissue inhibitor of matrixmetalloproteinases 1 (TIMP 1)."( Daidzein exhibits anti-fibrotic effect by reducing the expressions of Proteinase activated receptor 2 and TGFβ1/smad mediated inflammation and apoptosis in Bleomycin-induced experimental pulmonary fibrosis.
Divya, T; Kalayarasan, S; Soumyakrishnan, S; Sriram, N; Sudhandiran, G, 2014
)
2.18
"Treatment with daidzein (10 mg/kg, i.p.) 1 h prior to the ischemia/reperfusion procedure (I/R) reduced the infarct size by 52.8% (P<0.05). "( Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-kappaB activation.
Chang, KC; Ha, YL; Jin, YC; Kim, HJ; Kim, JW; Kim, YM; Lee, JH; Rhie, S; Seo, HG, 2009
)
2.15
"Oral treatment with daidzein or equol at a human equivalent dose suppressed the growth of both DMBA-induced mammary tumors and human MCF-7 breast cancer xenografts in rodents, the inhibitory activity being superior to that of genistein or tamoxifen. "( Anti-breast cancer potential of daidzein in rodents.
Liu, X; Okamoto, Y; Santosh Laxmi, YR; Shibutani, S; Suzuki, N, 2012
)
0.99
"Treatment of daidzein at 10, 50 and 100 microM resulted in cell cycle arrest at G0/G1 phase, DNA fragmentation and increases in caspase-3 activity."( Biphasic effect of daidzein on cell growth of human colon cancer cells.
Grant, M; Guo, JM; Guo, YB; Lai, YF; Liu, DH; Liu, Q; Xiao, BX; Zhang, S, 2004
)
1
"Treatment with daidzein resulted in increased expression of FSHR mRNA in LWF, SYF, and granulosa layers of F4 to F2 and LHR mRNA in granulosa layers of F4 and F1 (P < 0.05)."( Effects of daidzein on messenger ribonucleic Acid expression of gonadotropin receptors in chicken ovarian follicles.
Liu, HY; Zhang, CQ, 2008
)
1.08

Toxicity

Daidzein has become increasingly popular as a dietary supplement, particularly for postpeak-estrus animals, as a safe and natural alternative estrogen-like compound. It is surprising that, contrary to estrogen, isoflavones, specifically genistein and daidze in, are toxic to primary neuronal culture at high concentration.

ExcerptReferenceRelevance
"3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine."( 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000
)
0.31
" However, adverse health effects of phytoestrogens have often been ignored."( Genotoxicity of phytoestrogens.
Kobras, K; Schmitt, E; Stopper, H, 2005
)
0.33
" It is surprising that, contrary to estrogen, isoflavones, specifically genistein and daidzein, are toxic to primary neuronal culture at high concentration."( Genistein and daidzein induce neurotoxicity at high concentrations in primary rat neuronal cultures.
Cohen, EM; Jin, H; Jin, Y; Prentice, H; Wei, J; Wu, H; Wu, JY, 2007
)
0.92
"active and placebo-treated subjects exhibited a comparable side-effect profile."( A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women.
Asthana, S; Atwood, CS; Barnet, JH; Carlsson, CM; Gleason, CE; Johnson, SC; Meade, SA; Ries, ML; Setchell, KD, 2009
)
0.35
"The current investigations were undertaken to study the mechanism of the adverse effect of phytoestrogens on the function of bovine granulosa (follicles >1< cm in diameter) and luteal cells from day 1-5, 6-10, 11-15, 16-19 of the oestrous cycle."( The adverse effect of phytoestrogens on the synthesis and secretion of ovarian oxytocin in cattle.
Kotwica, J; Mlynarczuk, J; Wrobel, MH, 2011
)
0.37
" These results indicate that isoflavones can be considered safe compounds."( Red clover and soy isoflavones--an in vitro safety assessment.
Gerster, P; Jungbauer, A; Reiter, E, 2011
)
0.37
" PPI/daidzein complex is much more toxic than PAMAM/daidzein complex on several cell lines."( Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities.
Cheng, Y; Ding, L; Shao, N; Su, Y; Wang, Y; Yan, X; Ye, X; Zhang, H; Zhao, C; Zhao, D, 2011
)
0.88
"Daidzein, an estrogen-like product, has become increasingly popular as a dietary supplement, particularly for postpeak-estrus animals seeking a safe natural alternative to play a role of estrogen."( Safety evaluation of daidzein in laying hens: part II. Effects on calcium-related metabolism.
Chang, LL; Gu, H; Shi, SR; Tong, HB; Wang, ZY; Zou, JM, 2013
)
2.15
"Daidzein, an estrogen-like product, becomes increasingly popular as a dietary supplement, particularly for postpeak-estrus animals seeking a safe natural alternative to play a role of estrogen."( Safety evaluation of daidzein in laying hens: part I. Effects on laying performance, clinical blood parameters, and organs development.
Chang, LL; Gu, H; Shi, SR; Tong, HB; Wang, ZY; Zou, JM, 2013
)
2.15
"Daidzein has become increasingly popular as a dietary supplement, particularly for postpeak-estrus animals, as a safe and natural alternative estrogen-like compound."( Safety evaluation of daidzein in laying hens: Effects on laying performance, hatchability, egg quality, clinical blood parameters, and organ development.
Dou, TC; Hu, YP; Li, SM; Lu, J; Qu, L; Shen, MM; Wang, KH, 2017
)
2.22
" No adverse events were elicited."( Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women.
Brinton, RD; Chen, YL; Franke, AA; Hernandez, G; Mack, WJ; Schneider, LS; Zhao, L, 2018
)
0.48
"A single-dose oral administration of the phytoSERM formulation was well-tolerated and did not elicit any adverse events."( Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women.
Brinton, RD; Chen, YL; Franke, AA; Hernandez, G; Mack, WJ; Schneider, LS; Zhao, L, 2018
)
0.48
" Adverse events occurred in 16."( Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.
Brinton, RD; Chen, YL; Franke, AA; Hernandez, G; Mack, WJ; Pawluczyk, S; Schneider, LS; Zhao, L, 2019
)
0.51

Pharmacokinetics

Daidzein has a wide range of pharmacodynamic properties in the treatment of cancer, neurodegenerative disorders, cardiac disorders, diabetes and its complication, osteoporosis, and skin disorders. The aim of this study was to evaluate the impact of nano-formulations (nanoemulsion-NE and nanosuspension-NS) prepared to increase the oral bioavailability of daidzeIn.

ExcerptReferenceRelevance
" We conducted a pharmacokinetic study of soybean isoflavones in seven healthy male volunteers."( Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako).
Adlercreutz, H; Arai, Y; Mazur, W; Miura, T; Sobue, T; Takahashi, T; Wähälä, K; Watanabe, S; Yamaguchi, M, 1998
)
0.3
" The half-life of both compounds was estimated to be 10-fold longer in the ESRD patients than in the healthy subjects."( Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients.
Custer, LJ; Fanti, P; Franke, AA; Sawaya, BP, 1999
)
0.54
" The apparent terminal half-life for daidzein sulfate (3."( Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein.
Badger, TM; Cimino, CO; Shelnutt, SR; Wiggins, PA, 2000
)
0.8
"We conducted safety studies of purified unconjugated genistein, daidzein, and glycitein, and defined pharmacokinetic parameters for their absorption and metabolism."( Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men.
Black, T; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Heizer, WD; Hill, JM; Jeffcoat, AR; Koch, MA; Thomas, BF; Zeisel, SH, 2002
)
0.55
"Isoflavones have pharmacokinetic characteristics that suggest that once-daily administration is adequate when they are administered long-term as dietary supplements."( Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense).
Howes, J; Howes, LG; Huang, L; Waring, M, 2002
)
0.31
"The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal women."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.52
" The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.31
" The mean volume of distribution normalized to bioavailability (V(d)/F), clearance rate, and half-life of [(13)C]daidzein were 336."( Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women.
Avades, T; Botting, NP; Brashear, WT; Brown, NM; Cassidy, A; Desai, P; Faughnan, MS; Oldfield, MF; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2003
)
0.81
" By comparing the pharmacokinetic parameters of theophylline before and after daily treatment with daidzein, the effect of daidzein on the metabolism of theophylline was evident."( Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers.
Li, HD; Peng, WX; Zhou, HH, 2003
)
0.94
"A phase I clinical trial was conducted to determine the safety, pharmacokinetic parameters, and efficacy of orally administered isoflavones (genistein and daidzein, potential cancer chemotherapeutic agents) over a 3-mo period in men with prostate neoplasia."( Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia.
Boan, J; Crowell, JA; Fischer, L; Jeffcoat, AR; Koch, MA; Mahoney, C; Stinchcombe, T; Thomas, BE; Valentine, JL; Zeisel, SH, 2004
)
0.52
"We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai women."( Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Anupongsanugool, E; Pongsatha, S; Rojanasthien, N; Sangdee, C; Teekachunhatean, S, 2005
)
0.61
" For pharmacokinetic parameters of daidzein, the mean values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations."( Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Anupongsanugool, E; Pongsatha, S; Rojanasthien, N; Sangdee, C; Teekachunhatean, S, 2005
)
0.89
" The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the dose, Tmax and t1/2, were not different between both soy preparations."( Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Anupongsanugool, E; Pongsatha, S; Rojanasthien, N; Sangdee, C; Teekachunhatean, S, 2005
)
0.88
" The pharmacokinetic parameters were calculated and analyzed statistically using the Student's t-test."( Influence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in rats.
Chen, XY; Liu, CX; Qiu, F; Song, B; Zhong, DF, 2005
)
0.58
" The assay was applied to the analysis of samples from a pharmacokinetic study."( Validation of an HPLC method for the simultaneous determination of DZ5 and its active metabolite in dog plasma and its pharmacokinetics.
Bi, D; Chen, J; Wang, S; Xiang, H; Zou, Y, 2006
)
0.33
" This HPLC method was applied successfully to the pharmacokinetic study of two kinds of daidzein-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (D-NPs) and daidzein suspension after intravenous injection in rats."( An HPLC method for the pharmacokinetic study of daidzein-loaded nanoparticle formulations after injection to rats.
Ma, Y; Shen, Q; Zhao, X, 2011
)
0.85
" The permeability study samples were analyzed by HPLC-PDA method; whereas the pharmacokinetic study, protein binding and whole blood partitioning samples were analyzed by LC-MS/MS method."( PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone.
Jain, GK; Pradhan, T; Singh, SP; Tewari, D, 2011
)
0.37
"3%, area under the concentration curve (AUC0-24) +24."( Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women.
Benvenuti, C; Setnikar, I, 2011
)
0.37
" The validated method was successfully applied to pharmacokinetic study of the seven components in female rat plasma after oral administration of Ge-Gen Decoction aqueous extract."( Simultaneous determination of puerarin, daidzin, daidzein, paeoniflorin, albiflorin, liquiritin and liquiritigenin in rat plasma and its application to a pharmacokinetic study of Ge-Gen Decoction by a liquid chromatography-electrospray ionization-tandem m
Chai, CZ; Huo, LX; Wang, DW; Wu, J; Xiao, HH; Yan, Y; Yu, BY; Zhu, DN, 2014
)
0.66
" The pharmacokinetic parameters (AUC0-24/dose and Cmax/dose) of the isoflavones from the two preparations differed significantly."( Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma.
de la Torre, R; Farré, M; Martínez-Riera, R; Papaseit, E; Pérez-Mañá, C; Pizarro, N; Rodríguez-Morató, J, 2015
)
0.42
" These results support the potential of this method for successful application in pharmacokinetic studies."( Metabolite Identification and Pharmacokinetic Profiling of Isoflavones from Black Soybean in Rats Using Ultrahigh-Performance Liquid Chromatography with Linear-Ion-Trap-Orbitrap and Triple-Quadrupole Tandem Mass Spectrometry.
Bai, J; Guo, Q; Huang, J; Liu, Y; Qiu, X; Su, Z; Wei, M; Zhang, J, 2018
)
0.48
" Furthermore, the method was successfully applied for pharmacokinetic study of these seven components in rat serum after oral administration of NDS."( Validated LC-MS/MS method for simultaneous quantification of seven components of Naodesheng in rat serum after oral administration and its application to a pharmacokinetic study.
Kang, J; Liang, S; Luo, L; Qi, Y; Zhao, W, 2019
)
0.51
"A physiologically based pharmacokinetic (PBPK) model was developed for daidzein and its metabolite S-equol."( Use of Physiologically Based Pharmacokinetic Modeling to Predict Human Gut Microbial Conversion of Daidzein to S-Equol.
Boonpawa, R; Rietjens, IMCM; Spenkelink, B; Wang, Q, 2022
)
1.17
" The aim of this study was to evaluate the impact of nano-formulations (nanoemulsion-NE and nanosuspension-NS) prepared to increase the oral bioavailability of daidzein, a poorly water-soluble isoflavone, on the pharmacokinetic parameters of daidzein in rats."( Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
Akıllıoğlu, K; Aksu, F; Cetin, M; Demirtürk, E; Dönmez Kutlu, M; Köse, S; Ugur Kaplan, AB, 2022
)
1.18
" Daidzein has a wide range of pharmacodynamic properties in the treatment of cancer, neurodegenerative disorders, cardiac disorders, diabetes and its complication, osteoporosis, and skin disorders."( Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone.
Kulkarni, YA; Laddha, AP, 2023
)
2.06

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"The crude methanol extract of Pueraria lobata was investigated by dual high-resolution α-glucosidase inhibition and radical scavenging profiling combined with hyphenated HPLC-HRMS-SPE-NMR."( Dual high-resolution α-glucosidase and radical scavenging profiling combined with HPLC-HRMS-SPE-NMR for identification of minor and major constituents directly from the crude extract of Pueraria lobata.
Jäger, AK; Kongstad, KT; Liu, B; Nyberg, NT; Qinglei, S; Staerk, D, 2015
)
0.42
"To verify synergistic effects, we investigated the antimicrobial activity of seven phenolic phytochemicals (gallic acid; epicatechin; epigallocatechin gallate; daidzein; genistein; myricetin; 3-hydroxy-6-methoxyflavone) in combination with six antibiotics against multidrug-resistant isolates from the ESKAPE group."( Synergistic antimicrobial activities of epigallocatechin gallate, myricetin, daidzein, gallic acid, epicatechin, 3-hydroxy-6-methoxyflavone and genistein combined with antibiotics against ESKAPE pathogens.
Borchardt, J; Böttcher, I; Buchmann, D; Guenther, S; Schaufler, K; Schultze, N, 2022
)
1.15
"The aim of this study is to demonstrate the potential use of phenolic natural compounds in combination with conventional antibiotics against multidrug-resistant bacteria of the ESKAPE group."( Synergistic antimicrobial activities of epigallocatechin gallate, myricetin, daidzein, gallic acid, epicatechin, 3-hydroxy-6-methoxyflavone and genistein combined with antibiotics against ESKAPE pathogens.
Borchardt, J; Böttcher, I; Buchmann, D; Guenther, S; Schaufler, K; Schultze, N, 2022
)
0.95

Bioavailability

The effects of bioavailability and metabolic transformation on the biological activities of daidzein are relatively unknown. This study aims to improve the solubility and bioavailability of diedzein by preparing the β-cyclodextrin-daidze in/PEG_(20000) nanocrystals.

ExcerptReferenceRelevance
" These data suggest that human isoflavone bioavailability depends upon the relative ability of gut microflora to degrade these compounds."( Bioavailability of soybean isoflavones depends upon gut microflora in women.
Harris, KS; Hendrich, S; Murphy, PA; Wang, HJ; Xu, X, 1995
)
0.29
" Re-infused genistein 7-O-beta-glucuronide was also well absorbed from the gut, although this occurred in the distal small intestine."( Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues.
Barnes, S; Coward, L; Kirk, M; Sfakianos, J, 1996
)
0.29
"This study compared the bioavailability of conjugates of the soy isoflavones genistein and daidzein in rats."( Daidzein conjugates are more bioavailable than genistein conjugates in rats.
King, RA, 1998
)
1.96
"22 microg/ml, respectively, indicating systemic bioavailability of these substances."( Decreased ovarian hormones during a soya diet: implications for breast cancer prevention.
Anderson, KE; Grady, JJ; Kohen, F; Lu, LJ; Nagamani, M, 2000
)
0.31
"05) absorption rate during small intestinal passage."( Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine.
Andlauer, W; Fürst, P; Kolb, J, 2000
)
0.31
"The influence of dietary fructooligosaccharides (FOS) on bioavailability of genistein and daidzein in rats was estimated by measuring their concentrations in plasma collected from three different veins and in urine after a single intragastric administration of isoflavone conjugates."( Dietary fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and daidzein and affect their urinary excretion and kinetics in blood of rats.
Adlercreutz, H; Ohta, A; Sakai, K; Suzuki, K; Uehara, M; Watanabe, S, 2001
)
0.75
" The results suggest that daidzein is only poorly absorbed from the gastrointestinal tract in rodents."( Disposition and biotransformation of the estrogenic isoflavone daidzein in rats.
Bayer, T; Colnot, T; Dekant, W, 2001
)
0.85
" The application of LC/MS/MS to analyze isoflavone metabolites is simple and sensitive, and appears to be an excellent method for determining the bioavailability and metabolism of food phytochemistry."( Characterization of isoflavones and their conjugates in female rat urine using LC/MS/MS.
Badger, TM; Fang, N; Yu, S, 2002
)
0.31
" These results suggest that FOS increase the bioavailability of isoflavones, leading to cooperative effects in the prevention of osteopenia in OVX mice."( A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice.
Adlercreutz, H; Ishimi, Y; Morohashi, T; Ohta, A; Sakai, K; Takasaki, M; Uehara, M, 2002
)
0.31
" Controversy exists regarding the extent of bioavailability of isoflavone glycosides, and the mechanism of intestinal absorption of isoflavones in humans is unclear."( Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability.
Brashear, WT; Brown, NM; Heubi, JE; Kirschner, AS; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2002
)
0.31
" Bioavailability of isoflavones was confirmed by gas chromatography-mass spectrometry analysis."( Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability.
Brashear, WT; Brown, NM; Heubi, JE; Kirschner, AS; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2002
)
0.31
"Isoflavone glycosides are not absorbed intact across the enterocyte of healthy adults, and their bioavailability requires initial hydrolysis of the sugar moiety by intestinal beta-glucosidases for uptake to the peripheral circulation."( Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability.
Brashear, WT; Brown, NM; Heubi, JE; Kirschner, AS; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2002
)
0.31
" The systemic bioavailability and maximum serum concentration of [(13)C]genistein were significantly greater than those of [(13)C]daidzein."( Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women.
Avades, T; Botting, NP; Brashear, WT; Brown, NM; Cassidy, A; Desai, P; Faughnan, MS; Oldfield, MF; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2003
)
0.8
" The bioavailability of both isoflavones was nonlinear at higher intakes, suggesting that uptake is rate-limiting and saturable."( Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women.
Avades, T; Botting, NP; Brashear, WT; Brown, NM; Cassidy, A; Desai, P; Faughnan, MS; Oldfield, MF; Setchell, KD; Wolfe, BE; Zimmer-Nechemias, L, 2003
)
0.6
" A curvilinear relationship was observed between the bioavailability of daidzein and genistein, apparent from the area under the curve to infinity (AUC(inf)) of the serum concentration-time profiles and the amount of isoflavones ingested."( Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes.
Brown, NM; Creutzinger, V; Desai, PB; Heubi, JE; Jakate, AS; Setchell, KD; Wolfe, B; Zimmer-Nechimias, L, 2003
)
0.55
"Test results on the bioavailability of isoflavones in the aglycone or glucoside form in Eastern and Western human subjects are contradictory."( Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women.
Meydani, M; Zubik, L, 2003
)
0.32
"The objective was to investigate the bioavailability of the soy isoflavones daidzein and genistein in American women with typical American dietary habits after ingestion of the aglycone or glucoside form of isoflavones."( Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women.
Meydani, M; Zubik, L, 2003
)
0.55
"The apparent bioavailability of genistein and daidzein is not different when consumed as either aglycone or glucoside by American women."( Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women.
Meydani, M; Zubik, L, 2003
)
0.58
" MRP type efflux pumps may limit the bioavailability of EGCG."( Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
Hong, J; Lambert, JD; Lee, SH; Sinko, PJ; Yang, CS, 2003
)
0.32
"Little information is currently available on the role of the gut microflora in modulating isoflavone bioavailability or on sex differences in isoflavone metabolism and bioavailability."( Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults.
Bowey, EA; Casey, K; Clarke, DB; Davies, M; Duffy, R; Lloyd, AS; Murray, A; Rowland, IR; Thompson, R; Wiseman, H, 2004
)
0.32
"We sought to determine whether chronic soy consumption influences isoflavone bioavailability as judged by plasma isoflavone concentrations and modified gut microflora activities [beta-glucoside hydrolysis and equol and O-desmethylangolensin (O-DMA) production]."( Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults.
Bowey, EA; Casey, K; Clarke, DB; Davies, M; Duffy, R; Lloyd, AS; Murray, A; Rowland, IR; Thompson, R; Wiseman, H, 2004
)
0.32
" The results confirm the expected differences in the bioavailability of soy isoflavones, yet, there were no significant differences in performance of pigs fed either soy bean meal or soy protein concentrate."( Growth performance, carcass characteristics and bioavailability of isoflavones in pigs fed soy bean based diets.
Degen, GH; Hennig, U; Kalbe, C; Kuhn, G; Moors, S; Rehfeldt, C; Ren, MQ, 2004
)
0.32
" The purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai women."( Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Anupongsanugool, E; Pongsatha, S; Rojanasthien, N; Sangdee, C; Teekachunhatean, S, 2005
)
0.82
"The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules, whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were comparable."( Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
Anupongsanugool, E; Pongsatha, S; Rojanasthien, N; Sangdee, C; Teekachunhatean, S, 2005
)
0.92
"If soy isoflavones are to be effective in preventing or treating a range of diseases, they must be bioavailable, and thus understanding factors which may alter their bioavailability needs to be elucidated."( Absorption of isoflavones in humans: effects of food matrix and processing.
Bugel, S; Cassidy, A; de Pascual-Teresa, S; Hallund, J; Schroot, J; Talbot, D; Williams, CM, 2006
)
0.33
" The absolute bioavailability of total DZ5 and DZ4 was 41."( Validation of an HPLC method for the simultaneous determination of DZ5 and its active metabolite in dog plasma and its pharmacokinetics.
Bi, D; Chen, J; Wang, S; Xiang, H; Zou, Y, 2006
)
0.33
"It is unknown whether the bioavailability of isoflavones is affected by the concomitant ingestion of glucosides or aglycones."( Bioavailability of isoflavones after ingestion of soy beverages in healthy adults.
Harada, K; Ishikawa, F; Kano, M; Sawada, S; Takayanagi, T, 2006
)
0.33
" Intestinal microbiota plays an important role in the metabolism and bioavailability of isoflavones."( Isolation of an isoflavone-metabolizing, Clostridium-like bacterium, strain TM-40, from human faeces.
Shinohara, K; Tamura, M; Tsushida, T, 2007
)
0.34
" The concentrations of urinary daidzein and genistein observed during intervention demonstrated good compliance, and a corresponding increase in serum daidzein and genistein confirmed bioavailability of the isoflavone-rich foods; 33 of the 117 volunteers (28."( Monoclonal antibody-based time-resolved fluorescence immunoassays for daidzein, genistein, and equol in blood and urine: application to the Isoheart intervention study.
Adlercreutz, H; Barnard, G; Bugel, S; Cassidy, A; Dadd, T; Kohen, F; Marlin, S; Ogborne, RM; Piron, J; Powell, J; Talbot, DC, 2007
)
0.86
" The bioavailability of daidzein in the microspheres by intramuscular injection increased up to 39% in rats, suggesting that the cross-linked chitosan microspheres are a valuable system for the long-term delivery of isoflavones."( Optimized preparation of daidzein-loaded chitosan microspheres and in vivo evaluation after intramuscular injection in rats.
Chen, DW; Ge, YB; Xie, LP; Zhang, RQ, 2007
)
0.95
" Because of their bioactivity, isoflavone bioavailability has been extensively studied in humans."( Review of the factors affecting bioavailability of soy isoflavones in humans.
Nielsen, IL; Williamson, G, 2007
)
0.34
" Isoflavone bioavailability was assessed at the beginning and end of each 5-wk dietary period by sampling plasma and urine after a standardized soy meal."( Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet.
Astheimer, LB; Larkin, TA; Price, WE, 2007
)
0.34
"The weak or absence of effects of probiotic yogurt or resistant starch supplement to a chronic soy diet suggests that gut microflora were not modified in a manner that significantly affected isoflavone bioavailability or metabolism."( Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet.
Astheimer, LB; Larkin, TA; Price, WE, 2007
)
0.34
" Bioavailability is clearly a crucial factor influencing their bioefficacy and could explain these discrepancies."( Higher bioavailability of isoflavones after a single ingestion of a soya-based supplement than a soya-based food in young healthy males.
Asselineau, J; Bennetau-Pelissero, C; Chantre, P; Durand, M; Lamothe, V; Moore, N; Perez, P; Potier, M; Sauvant, P; Vergne, S, 2008
)
0.35
"In order to improve the solubility and bioavailability of a soy isoflavone extract (IFE), inclusion complexes (IFE-beta-CD) of the isoflavone extract with beta-cyclodextrin (beta-CD) were prepared and studied for their solubility and bioavailability."( Enhanced bioavailability of soy isoflavones by complexation with beta-cyclodextrin in rats.
Cho, NS; Chung, CB; Hwang, YI; Kim, DC; Kim, KH; Kim, TH; Kim, YH; Lee, SH; Yu, HJ, 2007
)
0.34
"The contribution of lactase to isoflavone bioavailability has not been clarified."( Low activities of intestinal lactase suppress the early phase absorption of soy isoflavones in Japanese adults.
Hachiya, S; Hara, H; Shigematsu, N; Shiomi, T; Tamura, A, 2008
)
0.35
"There are conflicting results in the literature on the bioavailability of isoflavones in the aglycone and the glucoside forms."( Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study.
Bub, A; Kulling, SE; Möseneder, J; Rüfer, CE; Stürtz, M; Winterhalter, P, 2008
)
0.61
"The systemic bioavailability (area under the curve; AUC(inf)), the maximal plasma concentration (C(max)), and the cumulative recovery of DAI in urine after administration of DG were 3-6 times greater than after the ingestion of DAI."( Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study.
Bub, A; Kulling, SE; Möseneder, J; Rüfer, CE; Stürtz, M; Winterhalter, P, 2008
)
0.61
"Our results show that DG exhibits a greater bioavailability than its aglycone when ingested in an isolated form."( Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study.
Bub, A; Kulling, SE; Möseneder, J; Rüfer, CE; Stürtz, M; Winterhalter, P, 2008
)
0.61
"Better knowledge of the bioavailability and metabolism of isoflavones in prostate tissue is needed to further investigate their mechanisms of action in the context of prostate cancer prevention."( Orally administered isoflavones are present as glucuronides in the human prostate.
Al-Maharik, N; Boiteux, JP; Botting, NP; Gil-Izquierdo, A; Guy, L; Manach, C; Remesy, C; Scalbert, A; Urpi-Sarda, M; Védrine, N, 2008
)
0.35
"Daidzein is a very good candidate for treating cardio-cerebrovascular diseases, but its poor oral absorption and bioavailability limit its curative efficacy."( The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Chen, L; Gao, Y; Gu, W; Li, Y; Xu, Z, 2008
)
2.17
" These results suggest that selected probiotic strains of Bifidobacterium can be used to speed up the release of daidzein, improving its bioavailability for absorption by colonic mucosa and/or biotransformation to S-equol by other intestinal microorganisms."( Bioconversion of soy isoflavones daidzin and daidzein by Bifidobacterium strains.
Amaretti, A; De Lucia, M; Leonardi, A; Pagnoni, UM; Raimondi, S; Roncaglia, L; Rossi, M, 2009
)
0.82
"There are limited reports on the bioavailability and pharmacokinetics of isoflavones in elderly humans and aged animals."( Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Cooke, GM; Gilani, GS; Robertson, P; Sepehr, E, 2009
)
0.35
" In conclusion, the bioavailability of phytoestrogens, especially when given in mixtures, is subject to high interindividual variation."( Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
Bolca, S; Bracke, M; De Keukeleire, D; Depypere, H; Heyerick, A; Possemiers, S; Verstraete, W; Wyns, C, 2009
)
0.35
"To study the role of β-glucosidase producing probiotic bacteria and yeast in the biotransformation of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk."( Bioconversion of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk by probiotic bacteria and yeast.
Rekha, CR; Vijayalakshmi, G, 2010
)
0.36
" Increase in bioavailability of minerals and vitamin B complex were also observed in fermented soymilk."( Bioconversion of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk by probiotic bacteria and yeast.
Rekha, CR; Vijayalakshmi, G, 2010
)
0.36
" boulardii has great potential for the enrichment of bioactive isoflavones, enhancing the viability of LAB strains, decreasing the antinutrient phytic acid and increasing the mineral bioavailability in soymilk fermentation."( Bioconversion of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk by probiotic bacteria and yeast.
Rekha, CR; Vijayalakshmi, G, 2010
)
0.36
"Fermentation of soymilk with probiotic organisms improves the bioavailability of isoflavones, assists in digestion of protein, provides more soluble calcium, enhances intestinal health and supports immune system."( Bioconversion of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk by probiotic bacteria and yeast.
Rekha, CR; Vijayalakshmi, G, 2010
)
0.36
" Cladrin had much better plasma bioavailability compared with formononetin."( Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats.
Bhargavan, B; Chattopadhyay, N; Gautam, AK; Jain, GK; Kumar, M; Manickavasagam, L; Maurya, R; Mishra, JS; Sanyal, S; Singh, A; Singh, AB; Singh, D; Singh, SP; Srivastava, K; Tyagi, AM; Wahajuddin, W; Yadav, DK, 2011
)
0.37
" However, flavonoid bioavailability is often poor probably due to their interaction with plasma proteins."( Flavonoid binding to human serum albumin.
Ascenzi, P; Bolli, A; Fanali, G; Fasano, M; Marino, M; Rimbach, G, 2010
)
0.36
" The S-equol BLEIA documented in this study is expected to be an important tool for the assessment of equol producer status and demonstration of the bioavailability of isoflavone."( Development of bioluminescent enzyme immunoassay for s-equol using firefly luciferase and its application to the assessment of equol-producer status.
Abe, K; Arakawa, H; Kambegawa, A; Maekawa, H; Minekawa, T; Ohkuma, H; Shindome, K, 2011
)
0.37
" The present study demonstrated that RS may increase the bioavailability of daidzein."( Resistant starch promotes equol production and inhibits tibial bone loss in ovariectomized mice treated with daidzein.
Abe, F; Ishida, T; Ishimi, Y; Tousen, Y; Uehara, M, 2011
)
0.81
" Urinary isoflavones are frequently used as a biomarker of isoflavone bioavailability from food or supplement since urine contains 100-fold higher concentrations of isoflavones."( Apparent bioavailability of isoflavones in urinary excretions of postmenopausal Malay women consuming tempeh compared with milk.
Azlan, A; Haron, H; Ismail, A; Peng, LS; Shahar, S, 2011
)
0.37
"To study on the dispersion of daidzein with polyvinylpyrrolidone (PVP) and its effects on the aqueous solubility, dissolution rate and bioavailability of daidzein."( Dispersion of daidzein with polyvinylpyrrolidone effects on dissolution rate and bioavailability.
Feng, BL; Li, HW; Lu, W; Zhou, MY, 2011
)
1.02
" In addition,the bioavailability of free daidzein as well as its solid dispersion were studied in mice."( Dispersion of daidzein with polyvinylpyrrolidone effects on dissolution rate and bioavailability.
Feng, BL; Li, HW; Lu, W; Zhou, MY, 2011
)
1
" The results of the bioavailability showed that both Cmax and AUC value of daidzein solid dispersion were about 5 times larger than unprocessed daidzein, implying that the rate-limiting step in daidzein absorption may be the dissolution process."( Dispersion of daidzein with polyvinylpyrrolidone effects on dissolution rate and bioavailability.
Feng, BL; Li, HW; Lu, W; Zhou, MY, 2011
)
0.96
"A self-assembled nano-based delivery system was designed and developed to increase the oral bioavailability of poor hydrophilic and lipophilic daidzein."( A self-assembled nanodelivery system enhances the oral bioavailability of daidzein: in vitro characteristics and in vivo performance.
Bu, H; Gao, F; Gao, Z; Gu, W; Huang, Y; Li, Y; Zhang, Z, 2011
)
0.8
"The presented delivery system could provide a new promising strategy for enhancing the oral bioavailability of drugs with poor hydrophilicity and lipophilicity."( A self-assembled nanodelivery system enhances the oral bioavailability of daidzein: in vitro characteristics and in vivo performance.
Bu, H; Gao, F; Gao, Z; Gu, W; Huang, Y; Li, Y; Zhang, Z, 2011
)
0.6
"To verify the single dose bioavailability of two oral formulations of soy isoflavones, with and without lactobacilli, in menopausal women in antibiotic therapy."( Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women.
Benvenuti, C; Setnikar, I, 2011
)
0.37
"8 mgkg(-1)day(-1), sc) and Atorvastatin (30 mgkg(-1)day(-1), po Positive Control) for one week markedly improved vascular endothelial dysfunction due to increase in nitric oxide bioavailability perhaps by inhibiting caveolin-1 and activation of PI3K-AKT pathway."( Ameliorative effect of daidzein: a caveolin-1 inhibitor in vascular endothelium dysfunction induced by ovariectomy.
Sharma, PL; Sharma, S; Singh, M, 2012
)
0.69
"The aim of this research was to increase the oral bioavailability of daidzein by the formulations of poly(lactic-co-glycolic) acid (PLGA) nanoparticles loaded with daidzein."( The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability.
Li, J; Ma, Y; Shen, Q; Zhao, X, 2012
)
0.91
" However, these studies cannot reflect the realistic effects that soy may induce through diets, and little is known about the bioavailability of isoflavones from whole soy food and their bioactivities after cooking and digestion."( Apoptotic effects of cooked and in vitro digested soy on human prostate cancer cells.
Dong, X; Sikes, RA; Wu, C; Xu, W, 2012
)
0.38
" The developed method, which was found to be sensitive, selective, precise and accurate, could be a valuable tool for research focused on determining the bioavailability of individual SERMs."( Development of a simple, fast, and accurate method for the direct quantification of selective estrogen receptor modulators using stable isotope dilution mass spectrometry.
Cohen, J; Hegeman, A; Ismail, B; Roe, M; Yerramsetty, V, 2013
)
0.39
" Determining enhancement in solubility and bioavailability we investigated the transport of these inclusion complexes across Caco-2 cell line comparing that of the pure compounds and found significant improving effect of the different CD derivatives on membrane permeation of the two isoflavone aglycons."( Investigation of transport of genistein, daidzein and their inclusion complexes prepared with different cyclodextrins on Caco-2 cell line.
Daruházi, AE; Kiss, T; Lemberkovics, E; Szente, L; Szőke, E; Vecsernyés, M, 2013
)
0.66
" These data suggest that the inhibition of SULTs by flavonoids and in vivo flavonoid conjugates may modify the bioavailability of dietary hydroxycinnamic acids by suppressing their conversion to sulfated metabolites."( Inhibition of hydroxycinnamic acid sulfation by flavonoids and their conjugated metabolites.
Williamson, G; Wong, CC,
)
0.13
" Bioavailability and metabolism of these red clover isoflavones (RCI) have not been studied in detail."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
"To determine the bioavailability of RCI metabolites and analyse whether FOS supplementation could influence their bioavailability."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" In the first, compound bioavailability was determined after consumption of 80 mg of RCI (MF11RCE)."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" Supplementation with FOS led to a significant decrease in the bioavailability of daidzein, dihydroformononetin, dihydrogenistein and dihydrodaidzein."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.64
"This study is the first to provide detailed data on RCI bioavailability in humans and determine no influence of FOS yet a trend toward increased equol production."( Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation.
Chedraui, P; Hobiger, S; Imhof, M; Jungbauer, A; Laschitz, T; Lipovac, M; Pfitscher, A, 2015
)
0.42
" The aim of this study was to investigate the effect of a fixed combination of soy isoflavones on the oral bioavailability of levothyroxine in post-menopausal female volunteers."( Evaluation of Levothyroxine Bioavailability after Oral Administration of a Fixed Combination of Soy Isoflavones in Post-menopausal Female Volunteers.
Barbetta, B; Benvenuti, C; Colovic, M; Donazzolo, Y; Giacovelli, G; Manzotti, C; Persiani, S; Rovati, LC; Sala, F; Vitalini, C; Zangarini, M, 2016
)
0.43
" A number of isoflavone extracts are commercially available, but there is little information concerning the specific isoflavone content of these products or differences in their bioavailability and pharmacokinetics."( Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma.
de la Torre, R; Farré, M; Martínez-Riera, R; Papaseit, E; Pérez-Mañá, C; Pizarro, N; Rodríguez-Morató, J, 2015
)
0.42
"The effects of bioavailability and metabolic transformation on the biological activities of daidzein are relatively unknown."( Relative Inhibitions of 5-Lipoxygenase and Myeloperoxidase and Free-Radical Scavenging Activities of Daidzein, Dihydrodaidzein, and Equol.
Loke, WM; Tan, XY; Tan, YM; Tsen, SY; Yan, BY, 2016
)
0.87
" This review focuses on providing a comprehensive account on the bioavailability and metabolism of daidzein in vivo, and discusses its activities and mechanisms of action in detail, in both physiological and pathological conditions."( Daidzein and its Effects on Brain.
Ahmed, T; Budzyńska, B; D'Onofrio, G; Daglia, M; Javed, S; Nabavi, SF; Nabavi, SM; Tariq, A, 2017
)
2.11
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"Daidzein, which is scarce in nature, has gained significant attention due to its superior biological activity and bioavailability compared with daidzin."( Highly Efficient Enzymatic Preparation of Daidzein in Deep Eutectic Solvents.
Cheng, QB; Zhang, LW, 2017
)
2.16
" Existing functional substances have been assessed as fermentation substrates for better component bioavailability or other functions."( Bioconversion Using Lactic Acid Bacteria: Ginsenosides, GABA, and Phenolic Compounds.
Lee, NK; Paik, HD, 2017
)
0.46
"Self-emulsifying phospholipid-complex preconcentrates (SEPPs) were fabricated to improve oral bioavailability of daidzein (DAI), an anticancer drug with challenging amphiphobic nature and extensive presystemic metabolism."( Self-emulsifying preconcentrates of daidzein-phospholipid complex: design, in vitro and in vivo appraisal.
Abdallah, OY; Elnaggar, YS; Galal, S; Shehata, EM, 2017
)
0.94
" This study investigated whether DJ improves the bioavailability of isoflavones compared to boiled soybean (BS) in sham-operated or ovariectomized (OVX) rats."( Bioavailability of Isoflavone Metabolites After Korean Fermented Soybean Paste (Doenjang) Ingestion in Estrogen-Deficient Rats.
Ahn, J; Ha, TY; Jang, YJ; Jung, CH; Kim, MJ; Lee, DH; Nam, YD; Park, SH; Song, EJ, 2018
)
0.48
" However, the bioavailability and clinical applications of flavonoid compounds are usually limited by their poor aqueous solubilities."( Simultaneously Improving the Physicochemical Properties, Dissolution Performance, and Bioavailability of Apigenin and Daidzein by Co-Crystallization With Theophylline.
Cai, T; Huang, S; Ruan, S; Xu, J; Xue, Q, 2019
)
0.72
"The purpose of this investigation was to improve the solubility and oral bioavailability of daidzein via preparing nanosuspensions (NS) with steric stabilizers, electrostatic stabilizers, or a combination of both."( Development of daidzein nanosuspensions: Preparation, characterization, in vitro evaluation, and pharmacokinetic analysis.
Du, R; Han, X; Ren, S; Sang, Z; Shi, X; Wang, H; Xiao, Y; Xie, Y, 2019
)
1.09
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Isoflavone aglycones (IFAs) of soybeans in human diets have poor solubility in water, resulting in low bioavailability and bioactivity."( Enrichment of Polyglucosylated Isoflavones from Soybean Isoflavone Aglycones Using Optimized Amylosucrase Transglycosylation.
Jang, D; Jung, YS; Kim, AT; Kim, DO; Kim, MS; Kim, YJ; Nam, TG; Park, CS; Rha, CS; Seo, DH, 2020
)
0.56
" PRACTICAL APPLICATIONS: The low water solubility and poor bioavailability of PUE and DAI limit their application."( Interactions between puerarin/daidzein and micellar casein.
Qin, J; Wa, W; Wang, Y; Yang, M, 2022
)
1.01
" The aim of this study was to evaluate the impact of nano-formulations (nanoemulsion-NE and nanosuspension-NS) prepared to increase the oral bioavailability of daidzein, a poorly water-soluble isoflavone, on the pharmacokinetic parameters of daidzein in rats."( Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
Akıllıoğlu, K; Aksu, F; Cetin, M; Demirtürk, E; Dönmez Kutlu, M; Köse, S; Ugur Kaplan, AB, 2022
)
1.18
"It revealed that nanoscale size is an important factor to overcome any dissolution rate barriers to oral bioavailability of the low water-soluble compound."( Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
Akıllıoğlu, K; Aksu, F; Cetin, M; Demirtürk, E; Dönmez Kutlu, M; Köse, S; Ugur Kaplan, AB, 2022
)
0.98
" These isoflavones generally have low solubility resulting in low bioavailability and bioactivity."( Bio-enhancement of Soy Isoflavones (Genistein & Daidzein) Using Bacillus coagulans in Letrozole Induced Polycystic Ovarian Syndrome by Regulating Endocrine Hormones in Rats.
Acharya, S; Bulsara, J; Desai, S; Halpati, K; Patil, P; Soni, A, 2022
)
0.98
" Certain pharmacokinetic properties of DAI such as less aqueous solubility, low permeability, and poor bioavailability are major obstacles restricting the therapeutic applications."( Unveiling the Pharmacological and Nanotechnological Facets of Daidzein: Present State-of-the-Art and Future Perspectives.
Anwer, MK; Behl, T; Bumbu, A; Bungau, SG; Grewal, S; Gupta, S; Mohan, S; Sharma, N; Singh, S; Vargas-De-La-Cruz, C, 2023
)
1.15
"This study aims to improve the solubility and bioavailability of daidzein by preparing the β-cyclodextrin-daidzein/PEG_(20000)/Carbomer_(940) nanocrystals."( [Preparation and in vitro property evaluation of β-cyclodextrin-daidzein/PEG_(20000)/Carbomer_(940) nanocrystals].
Chen, LH; Guan, YM; Ye, SH; Zang, ZZ; Zhou, X; Zhu, WF, 2023
)
1.39
"01) and had a relative bioavailability of 122%."( [Pharmacokinetics, pharmacodynamics, and tissue distribution of oral co-loaded puerarin/daidzein mixed micelles in rats].
Ge, SC; Guo, ZL; Kuang, WL; Li, WD; Liu, P; Wang, SD; Wu, WT; Zhou, ZW; Zhu, WF, 2023
)
1.13

Dosage Studied

Six-month consumption of whole soy and purified daidzein had no improvement on body weight and composition compared with isocaloric milk placebo among prehypertensive equol-producing postmenopausal women.

ExcerptRelevanceReference
" Plasma genistein concentration at 2 h after dosing was 11."( Absorption and excretion of the soy isoflavone genistein in rats.
Broadbent, JL; Head, RJ; King, RA, 1996
)
0.29
" Dose-response curves for genistein indicated a half-maximum effect at 60 microM."( Direct block of voltage-sensitive sodium channels by genistein, a tyrosine kinase inhibitor.
Carlier, E; Couraud, F; Dargent, B; Guedin, D; Paillart, C, 1997
)
0.3
" At the high glycitein dose (soygerm), plasma concentration at 24 h after dosing suggested a modest gender difference in glycitein bioavailability."( Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity.
Hendrich, S; Murphy, PA; Song, TT; Wang, GJ; Zhang, Y, 1999
)
0.56
" Eight sows received a dietary supplement of daidzein at a dosage of 8 mg per kg feed from day 85 of gestation, and six sows were used as controls."( Feeding daidzein to late pregnant sows influences the estrogen receptor beta and type 1 insulin-like growth factor receptor mRNA expression in newborn piglets.
Chen, J; Ender, K; Kuhn, G; Nürnberg, G; Ren, MQ; Wegner, J, 2001
)
1
"Trough plasma levels were significantly higher for daidzein and genistein after long-term dosing than levels taken prior to the commencement of the study and plasma levels of isoflavones after long-term dosing were in the range previously reported in populations that consume an isoflavone-rich diet."( Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense).
Howes, J; Howes, LG; Huang, L; Waring, M, 2002
)
0.57
" The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones."( Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.
Albright, C; Black, TM; Bloedon, LT; Busby, MG; Crowell, JA; Dix, KJ; Jeffcoat, AR; Lopaczynski, W; Schell, MJ; Thomas, BF; Zeisel, SH, 2002
)
0.31
" Among the three experiments, no significant differences were found in the proportion of glucuronide, sulfate and aglycone isoflavones recovered from plasma samples taken 3 h after isoflavone dosing or in 24-h urine samples taken after isoflavone dosing."( Glucuronides are the main isoflavone metabolites in women.
Hendrich, S; Murphy, PA; Zhang, Y, 2003
)
0.32
" It is believed that the observed activities were not generated by cell free cell culture conditions because increased responses were observed over and above control values when the compounds were added, and also increasing dose-response relationships have been found after treatment with such oestrogenic compounds in previously reported studies."( Oestrogenic compounds and oxidative stress (in human sperm and lymphocytes in the Comet assay).
Anderson, D; Baumgartner, A; Brinkworth, MH; Cemeli-Carratala, E; Schmid, TE; Wood, JM, 2003
)
0.32
" A trend to a greater percentage urinary recovery of daidzein and glycitein was observed among women consuming fermented soya milk at a dosage of 40 mg isoflavone (P=0."( Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soya milk fermented with probiotic bifidobacteria.
Shah, NP; Stojanovska, L; Tsangalis, D; Wilcox, G, 2005
)
0.58
"To investigate the influence of dosage forms on the pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in Wistar rats."( Influence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in rats.
Chen, XY; Liu, CX; Qiu, F; Song, B; Zhong, DF, 2005
)
0.82
"After administration of two typical dosage forms (daidzein solution and suspension), the concentrations of daidzein and daidzein-7-O-glucuronide were determined by an LC-MS-MS method."( Influence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in rats.
Chen, XY; Liu, CX; Qiu, F; Song, B; Zhong, DF, 2005
)
0.84
" However, there were significant increases in 7alpha- and 7beta-OOHs, 7alpha- and 7beta-OHs, and 7-keto after ethanol dosage compared to controls."( Protective effect of daidzein against acute ethanol-induced lipid peroxidation in rat jejunum.
Adachi, J; Nakagawa, K; Ueno, Y; Wong, MC, 2006
)
0.65
" Optimal dosage of genistein, quercetin and in combination with chemicals for leukemia cells were determined by experiments."( [Synergistic antileukemic effect of phytoestrogens and chemotherapeutic drugs on leukemic cell lines in vitro].
Chen, CS; Shen, J; Tai, YC; Wong, CH; Xie, Z; Zhang, WJ, 2008
)
0.35
" No significant differences in the bioavailability of daidzein were observed in aged rats dosed with aglycon, glucoside or Novasoy."( Effect of glycosidation of isoflavones on their bioavailability and pharmacokinetics in aged male rats.
Cooke, GM; Gilani, GS; Robertson, P; Sepehr, E, 2009
)
0.6
" At a dosage of 250 microg/pellet the red clover extract showed excellent inhibition of angiogenesis."( Inhibition of angiogenesis and inflammation by an extract of red clover (Trifolium pratense L.).
Krenn, L; Paper, DH, 2009
)
0.35
"The expressions of ERalpha mRNA and protein were significantly lower than that of ERbeta in three dosing groups."( [Role of the cross-talk between estrogen receptors and peroxisome proliferator-activated receptor gamma in daidzein's prevention and treatment of osteoporosis in ovariectomized rats].
Zhang, J; Zhang, R; Zhang, SF; Zou, SE, 2009
)
0.57
" In addition, no evidence of cytotoxicity or genotoxicity was seen in the rat bone marrow micronucleus test in animals dosed at levels up to the standard limit of 2000 mg/kg."( Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests.
Jackson, R; Proudlock, R; Schwen, R, 2010
)
0.36
" Isoformo at the concentration reaching the bone marrow achieved out of its most effective oral dosing induced stromal cell mineralization and osteogenic gene expression in the calvaria of neonatal rats."( Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Changkija, B; Chattopadhyay, N; Dixit, M; Jain, GK; Khan, K; Khan, MP; Kumar, A; Lahiri, S; Maurya, R; Nagar, GK; Singh, D; Singh, SP; Srivastava, K; Trivedi, R; Tyagi, AM; Yadav, DK, 2013
)
0.69
"Six-month consumption of whole soy and purified daidzein at provided dosage had no improvement on body weight and composition compared with isocaloric milk placebo among prehypertensive equol-producing postmenopausal women."( A six-month randomized controlled trial of whole soy and isoflavones daidzein on body composition in equol-producing postmenopausal women with prehypertension.
Chen, YM; Ho, SC; Liu, ZM; Woo, J, 2013
)
0.88
" Similarly, inverse associations with apparent dose-response relationships were found between isoflavone intakes and oesophageal cancer risk."( Soya and isoflavone intakes associated with reduced risk of oesophageal cancer in north-west China.
Binns, CW; Lee, AH; Lei, J; Tang, L; Xu, F; Zhang, T, 2015
)
0.42
" A hundred and seventy-five 30-day-old male Wistar rats were dosed orally by stomach tube every day for 35 days, with saline solution, low and high doses of genistein, daidzein and a mixture of both."( The effects of isoflavones on androgens and glucocorticoids during puberty on male Wistar rats.
Caceres, S; Illera, JC; Illera, MJ; Martinez-Fernandez, L; Millan, P; Monsalve, B; Peña, L; Silvan, G, 2014
)
0.6
" However, since the lack of clinical research for evaluation of the proper dosage of intake of soy isoflavones in diet or adjunctive therapy, there is a need for further studies on the selection of doses, biomedical applications and adverse effects of isoflavones for human health."( Soy Isoflavones and their Effects on Xenobiotic Metabolism.
He, P; Meng, C; Zhou, T, 2019
)
0.51
" Experimental animals were daily dosed orally with low and high doses of a mixture of two soy isoflavones (genistein and daidzein) during 6 weeks."( Effects of soya milk on reproductive hormones during puberty in male Wistar rats.
Caceres, S; Illera, JC; Illera, MJ; Millan, P; Moyano, G; Silván, G, 2019
)
0.72
" Significant dose-response inverse associations were observed between dietary soy protein and isoflavones (quartiles) and type 2 diabetes in women (incidence rate ratio, IRR = 0."( Sex-specific associations of habitual intake of soy protein and isoflavones with risk of type 2 diabetes.
Choi, BY; Kim, MK; Lee, YH; Shin, DH; Shin, MH; Woo, HW, 2021
)
0.62
" Nanoemulsion and nanosuspension formulations are beneficial dosage forms to increase the oral bioavailability of Biopharmaceutical Classification System (BCS) Class II and Class IV compounds."( Assessment of Pharmacokinetic Parameters of Daidzein-Containing Nanosuspension and Nanoemulsion Formulations After Oral Administration to Rats.
Akıllıoğlu, K; Aksu, F; Cetin, M; Demirtürk, E; Dönmez Kutlu, M; Köse, S; Ugur Kaplan, AB, 2022
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
phytoestrogenAny compound produced by a plant that happens to have estrogenic activity.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
EC 3.2.1.20 (alpha-glucosidase) inhibitorAn EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the action of a DNA-directed DNA polymerase (EC 2.7.7.7).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
7-hydroxyisoflavonesA hydroxyisoflavone compound having a hydroxy group at the 7-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
superpathway of pterocarpan biosynthesis (via daidzein)022
(-)-glycinol biosynthesis010
superpathway of pterocarpan biosynthesis (via formononetin)031
coumestrol biosynthesis011
daidzein conjugates interconversion016
isoflavonoid biosynthesis I014
formononetin biosynthesis011
daidzein conjugates interconversion017
isoflavonoid biosynthesis I120
(-)-glycinol biosynthesis011
superpathway of pterocarpan biosynthesis (via formononetin)334
superpathway of pterocarpan biosynthesis (via daidzein)026
daidzin and daidzein degradation311
Pterocarpan biosynthesis07

Protein Targets (132)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency17.88160.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.35480.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency31.95960.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.95960.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.81010.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
LuciferasePhotinus pyralis (common eastern firefly)Potency15.85350.007215.758889.3584AID1224835; AID411
thioredoxin reductaseRattus norvegicus (Norway rat)Potency11.92040.100020.879379.4328AID488773; AID588453; AID588456
RAR-related orphan receptor gammaMus musculus (house mouse)Potency21.53690.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency14.89200.004110.890331.5287AID493106; AID493107
NFKB1 protein, partialHomo sapiens (human)Potency4.46680.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency10.00000.35487.935539.8107AID624146
GLI family zinc finger 3Homo sapiens (human)Potency14.12290.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency23.44510.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency2.51190.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency23.15240.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency8.50180.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency34.50530.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency2.73950.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.33210.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency38.57080.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94570.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.99910.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency17.97010.001310.157742.8575AID1259252; AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency46.57790.000214.376460.0339AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency15.22460.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.75280.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency54.40370.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency24.67010.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.53300.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency0.21320.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency0.94500.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency7.30780.819914.830644.6684AID720573
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency14.12540.001024.504861.6448AID588534
arylsulfatase AHomo sapiens (human)Potency6.74561.069113.955137.9330AID720538
pyruvate kinaseLeishmania mexicana mexicanaPotency12.58930.398113.744731.6228AID945; AID959
caspase-3Homo sapiens (human)Potency8.50180.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency1.77190.016525.307841.3999AID504836; AID602332
aryl hydrocarbon receptorHomo sapiens (human)Potency13.69870.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.05090.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency24.33650.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency1.93030.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.50120.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.84890.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency9.20000.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency47.754823.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.86310.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.30960.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency26.58710.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency22.38720.010039.53711,122.0200AID588547
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency60.50940.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency5.56790.037617.082361.1927AID1259364; AID1259388
ras-related protein Rab-9AHomo sapiens (human)Potency10.00000.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency21.74680.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency0.41090.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency21.20140.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency20.48390.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency0.00500.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency25.11892.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency3.44090.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.21320.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.21320.01238.964839.8107AID1645842
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency3.44090.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.30960.00638.235039.8107AID883
Nuclear receptor ROR-gammaHomo sapiens (human)Potency1.18830.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.50121.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.21320.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.53400.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency18.70300.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.21320.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)36.83330.00000.503510.0000AID366284; AID366285; AID366286
rac GTPase-activating protein 1 isoform aHomo sapiens (human)IC50 (µMol)91.26007.390057.8904301.2400AID624330
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)IC50 (µMol)100.00000.03201.46494.8000AID1800156
Carbonic anhydrase 12Homo sapiens (human)Ki0.05640.00021.10439.9000AID1254159
Aldo-keto reductase family 1 member B10Homo sapiens (human)IC50 (µMol)32.20000.00101.94459.6000AID1265116
Carbonic anhydrase 1Homo sapiens (human)Ki10.00000.00001.372610.0000AID1254155
Carbonic anhydrase 2Homo sapiens (human)Ki10.00000.00000.72369.9200AID1254156
TransthyretinHomo sapiens (human)IC50 (µMol)16.00000.16004.292110.0000AID1074430
Estrogen receptorHomo sapiens (human)IC50 (µMol)175.42670.00000.723732.7000AID1855803; AID241876; AID356892; AID499822; AID70199; AID70335
Estrogen receptorHomo sapiens (human)Ki1.80000.00000.42297.9070AID70353
Aldehyde dehydrogenase, mitochondrialHomo sapiens (human)IC50 (µMol)9.00000.04003.40799.0000AID31427; AID34047
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)105.00000.00402.92669.9600AID753308
TyrosinaseMus musculus (house mouse)IC50 (µMol)500.00000.03002.21045.2300AID457084
AromataseHomo sapiens (human)Ki100.00000.00000.60469.5010AID387615
Urease subunit alphaHelicobacter pylori 26695IC50 (µMol)556.00000.29003.87606.7000AID745311
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)161.80000.00101.191310.0000AID1265119
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)100.00000.04002.099810.0000AID1800156
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)100.00000.10002.452310.0000AID1800156
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)14.00000.00002.37899.7700AID125222; AID125224
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)63.65000.30003.25807.3000AID1222388; AID1222389
Carbonic anhydrase 4Homo sapiens (human)Ki0.71870.00021.97209.9200AID1254157
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)14.00000.00001.89149.5700AID125222; AID125224
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)100.00000.00050.939410.0000AID1633148
Substance-P receptorCavia porcellus (domestic guinea pig)IC50 (µMol)37.10000.00002.751810.0000AID366285
Carbonic anhydrase 7Homo sapiens (human)Ki0.00420.00021.37379.9000AID1254158
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)714.90000.00132.81389.8200AID387151; AID387152
Urease subunit betaHelicobacter pylori 26695IC50 (µMol)556.00000.29003.87606.7000AID745311
TransporterRattus norvegicus (Norway rat)IC50 (µMol)0.45000.03000.30500.6400AID499822
Substance-K receptorCavia porcellus (domestic guinea pig)IC50 (µMol)37.10000.01500.01500.0150AID366285
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)1.65680.00010.529432.7000AID1855804; AID240680; AID361463; AID70514; AID70654
Estrogen receptor betaHomo sapiens (human)Ki0.30000.00000.12512.8760AID70660
Beta-hydroxyacyl-ACP dehydratase precursor (Fatty acid synthesis protein)Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)30.00000.03002.94428.0000AID265758
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorOvis aries (sheep)Kd5.90000.49002.03755.9000AID69702
Estrogen receptor betaOvis aries (sheep)Kd5.90000.49002.03755.9000AID69702
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucocorticoid receptorHomo sapiens (human)EC150 (µMol)10.10000.00053.62157.1000AID429117
Androgen receptorHomo sapiens (human)EC150 (µMol)10.10000.00053.58477.1000AID429115
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km400.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (404)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
carbohydrate metabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
alcohol metabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
ethanol catabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
aldehyde catabolic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
regulation of dopamine biosynthetic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
regulation of serotonin biosynthetic processAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (152)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
aldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
aldehyde dehydrogenase [NAD(P)+] activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
phenylacetaldehyde dehydrogenase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
electron transfer activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
nitroglycerin reductase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
NAD bindingAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
carboxylesterase activityAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (88)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
mitochondrionAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
extracellular exosomeAldehyde dehydrogenase, mitochondrialHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (310)

Assay IDTitleYearJournalArticle
AID1346840Human Estrogen-related receptor-alpha (3B. Estrogen-related receptors)2003Molecular cancer research : MCR, Nov, Volume: 1, Issue:13
Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors.
AID1346884Human Estrogen-related receptor-beta (3B. Estrogen-related receptors)2003Molecular cancer research : MCR, Nov, Volume: 1, Issue:13
Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors.
AID1346836Human Estrogen-related receptor-gamma (3B. Estrogen-related receptors)2003Molecular cancer research : MCR, Nov, Volume: 1, Issue:13
Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors.
AID1447205Reversible inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.01 mg/mL2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1764428Binding affinity to pig pancreatic lipase type 2 assessed as decrease in fluorescence intensity at 37 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID265764Inhibition of FabI at 100 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID334637Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID404179Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1447207Non-competitive inhibition of alpha glucosidase (unknown origin) using varying levels of alpha PNPG substrate at 0.01 mg/mL by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID690144Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID332645Inhibition of calf thymus DNA topoisomerase 1 catalytic domain-mediated supercoiled Escherichia coli pUC8 DNA relaxation up to 100 uM after 30 mins by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID456316ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID240680Binding affinity for human Estrogen receptor beta2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID265762Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID1656453Inhibition of rat liver beta-glucuronidase2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID318604Cytotoxicity against human NCIH460 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID499819Antiestrogenic activity at ER in human MCF7 cells assessed as inhibition of estradiol-induced transcriptional activity at 10 uM by luciferase reporter gene assay relative to estradiol2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID332646Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting up to 100 uM by agarose gel electrophoresis1995Journal of natural products, Feb, Volume: 58, Issue:2
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
AID1851305Antibacterial activity against Bacillus subtilis assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Biocatalytic synthesis and evaluation of antioxidant and antibacterial activities of hydroxyequols.
AID1127148Binding affinity to ERalpha (unknown origin) relative to estradiol2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor.
AID125222Inhibition of Hamster Liver mitochondrial Monoamine oxidase.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID1447215Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.01563 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID499824Estrogenic activity in human MCF7 cells assessed as increase of estradiol-induced cell proliferation at 1 uM after 48 hrs by clonogenic assay relative to control2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID429115Agonist activity at androgen receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID1281913Induction of apoptosis in human BGC823 cells at 80 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 1.5%)2016European journal of medicinal chemistry, Apr-13, Volume: 112Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
AID366287Cytotoxicity against MDCK cells by MTT assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID358171Inhibition of EGFR in human A431 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID366288Antiviral activity against Influenza A virus Jinan/15/90 H3N2 assessed as reduction of virus-induced cytopathic effect2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID406995Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID361463Displacement of [3H]estradiol from human recombinant ERbeta2002Journal of natural products, Dec, Volume: 65, Issue:12
Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
AID365150Activity for Streptomyces coelicolor A3(2) prenyltransferase assessed as formation of 7-(3,7-dimethylocta-2,6-dienyloxy)-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Chemoenzymatic syntheses of prenylated aromatic small molecules using Streptomyces prenyltransferases with relaxed substrate specificities.
AID596673Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 30 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1254155Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID690143Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID1265118Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate at 20 uM incubated for 15 mins by HPLC method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
AID1651897Inhibition of recombinant human PTP1B (1 to 321 residues) expressed in Escherichia coli at 10 uM using p-nitrophenyl phosphate as substrate incubated for 30 mins relative to control
AID1764435Binding affinity to pig pancreatic lipase type 2 assessed as binding constant at 27 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID387615Inhibition of human aromatase expressed in CHO cells2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Screening of herbal constituents for aromatase inhibitory activity.
AID456318DPPH radical scavenging activity assessed as trolox equivalent antioxidant capacity2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1204997Antioxidant activity of the compound assessed as inhibition of ABTS radicals after 20 mins by spectrophotometric analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Dual high-resolution α-glucosidase and radical scavenging profiling combined with HPLC-HRMS-SPE-NMR for identification of minor and major constituents directly from the crude extract of Pueraria lobata.
AID404692Inhibition of human salivary alpha-amylase2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID1222393Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation at 50 uM using >15 uM estradiol by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID265761Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID265765Inhibition of FabG at 100 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID503239Activity of Streptomyces antibioticus OleD P67T/S132F/A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID378965Antileishmanial activity against Leishmania donovani MHOM/SD/62/IS-CL2D axenic amastigotes after 3 days2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID690149Reducing activity by cyclic voltammetry2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID616383Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID366285Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1428455Renoprotective activity in pig LLC-PK1 cells assessed as inhibition of cisplatin-induced damage by measuring cell viability up to 100 uM preincubated for 24 hrs followed by addition of Ez-Cytox reagent and measured after 2 hrs relative to control2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Termisoflavones A-C, Isoflavonoid Glycosides from Termite-Associated Streptomyces sp. RB1.
AID358880Antifungal activity against wild type Candida albicans SC5314 after 24 hrs by XTT assay2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new phenolic compounds from a manipulated plant cell culture, Mirabilis jalapa.
AID361464Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay2002Journal of natural products, Dec, Volume: 65, Issue:12
Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
AID125224Inhibition of hamster liver mitochondrial monoamine oxidase MAO2001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Synthesis of potential antidipsotropic isoflavones: inhibitors of the mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway.
AID1744548Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID439371Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1374882Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Anti-inflammatory isoflavones and isoflavanones from the roots of Pongamia pinnata (L.) Pierre.
AID753308Inhibition of recombinant SARS coronavirus 3C-like protease trans-cleavage activity by ELISA2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
AID1447219Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID749999Binding affinity to recombinant paraoxonase-1 (unknown origin) expressed in Escherichia coli after 5 mins by Trp-fluorescence quenching method2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study.
AID1744549Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID457084Inhibition of tyrosinase in mouse Melan-a cells by ELISA2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
AID499821Displacement of fluorescent labeled ES2 from recombinant ERalpha relative to estradiol2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID84344Accumulation of 5 HIAL in isolated Hamster Liver Mitochondria at 0.9 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID756489Cytotoxicity against mouse RAW264.7 cells by CCK assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Inhibitory constituents of the heartwood of Dalbergia odorifera on nitric oxide production in RAW 264.7 macrophages.
AID596671Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID690148Reducing activity assessed as chlorogenic acid equivalent per mmol standard at 37 degC for 30 mins by Folin-Ciocalteu reagent assay assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID365335Ratio of Kcat to Km of Streptomyces coelicolor A3(2) prenyltransferase assessed as formation of 7-(3,7-dimethylocta-2,6-dienyloxy)-3-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Chemoenzymatic syntheses of prenylated aromatic small molecules using Streptomyces prenyltransferases with relaxed substrate specificities.
AID493896Glucose uptake enhancing activity in insulin-stimulated mouse 3T3L1 cells at 10 uM after 4 days by FLIPR based 2-DG uptake assay relative to control2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Glucose uptake enhancing activity of puerarin and the role of C-glucoside suggested from activity of related compounds.
AID404181Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1744554Octanol-water distribution coefficient, log D of the compound at pH 7.4 after 1 hr by UV-VIS spectroscopic analysis2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1254158Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID1428452Antifungal activity against Cryptococcus neoformans H99 by CLSI M27-A3 broth microdilution method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Termisoflavones A-C, Isoflavonoid Glycosides from Termite-Associated Streptomyces sp. RB1.
AID69702Displacement of [3H]-estradiol (E2) from sheep uterine estrogen receptor2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
AID70353Inhibition of binding of 17 beta-estradiol to human Estrogen receptor alpha2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID404180Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1082303Drug metabolism in fourth instar larval stage of Spodoptera litura assessed in excrements after feeding diet containing compound by HPLC analysis2011Journal of agricultural and food chemistry, Jun-08, Volume: 59, Issue:11
Secondary metabolites from Glycine soja and their growth inhibitory effect against Spodoptera litura.
AID1616108Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Recent advancements in mechanistic studies and structure activity relationship of F
AID265758Inhibition of FabZ2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
AID377875Antifungal activity against Giardia intestinalis ATCC 30888 after 48 hrs by XTT assay2000Journal of natural products, Oct, Volume: 63, Issue:10
Antigiardial activity of isoflavones from Dalbergia frutescens bark.
AID1265116Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate incubated for 15 mins by HPLC method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
AID1447214Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.03125 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1065095Agonist activity at estrogen receptor-alpha in human MCF7 cells by ERE-luciferase reporter gene assay2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.
AID456194Inhibition of beta amyloid (1 to 40) fibril formation2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
AID1222391Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation at 6.25 uM by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID1764426Binding affinity to pig pancreatic lipase type 2 assessed as decrease in fluorescence intensity at 27 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID378966Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221 after 72 hrs2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID481717Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
AID256508Inhibitory activity against Topoisomerase I2005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
A new synthesis of isoaurones: cytotoxic activity of compounds related to the alleged structure of isoaurostatin.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID70514Binding affinity against human estrogen receptor beta (ER beta) in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID265292Increase in ALP activity in mouse primary osteoblasts at 10 uM relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Osteoblast differentiation stimulating activity of biflavonoids from Cephalotaxus koreana.
AID406997Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1764422Inhibition of pig pancreatic lipase type 2 using p-nitrophenyl butyrate as substrate preincubated with enzyme for 10 mins followed by susbtrate addition and measured after 30 mins by spectrophotometric analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID439368Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1428451Antifungal activity against Candida albicans SC5314 by CLSI M27-A3 broth microdilution method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Termisoflavones A-C, Isoflavonoid Glycosides from Termite-Associated Streptomyces sp. RB1.
AID265293Increase in ALP activity in mouse primary osteoblasts at 20 uM relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Osteoblast differentiation stimulating activity of biflavonoids from Cephalotaxus koreana.
AID406994Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 20 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1855803Displacement of EL red from human full-length ER-alpha expressed in baculovirus expression system incubated for 2 hrs by fluorescence polarization assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An overview on Estrogen receptors signaling and its ligands in breast cancer.
AID457085Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
AID1222392Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation at 6.25 uM using 4 uM estradiol by LC-MS/MS method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID1222389Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID387150Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID1651900Induction of glucose uptake in human insulin resistant HepG2 cells at 10 uM incubated for 24 hrs by GOD-POD method relative to control
AID1851309Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Biocatalytic synthesis and evaluation of antioxidant and antibacterial activities of hydroxyequols.
AID1764434Binding affinity to pig pancreatic lipase type 2 assessed as quenching rate constant at 37 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID31427Inhibition of Hamster Liver mitochondrial ALDH-22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID378967Cytotoxicity against african green monkey Vero cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID84187Evaluated for percentage inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at the 9 uM2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID429117Agonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID1082304Insecticidal activity against fourth instar larval stage of Spodoptera litura in glandless fresh cabbage leaves assessed as growth inhibition measured 3 days after feeding diet containing compound2011Journal of agricultural and food chemistry, Jun-08, Volume: 59, Issue:11
Secondary metabolites from Glycine soja and their growth inhibitory effect against Spodoptera litura.
AID366286Inhibition of Influenza A Jiangsu/10/2003 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID499822Displacement of fluorescent labeled ES2 from recombinant ERalpha2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID1764423Binding affinity to pig pancreatic lipase type 2 assessed as Stern-Volmer quenching constant at 27 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID429127Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity at 100 uM by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1265119Inhibition of recombinant N-terminal His6-tagged AKR1B1 (unknown origin) expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate incubated for 15 mins by HPLC method2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
AID358879Antifungal activity against MDR knockout Candida albicans DSY1024 after 24 hrs by XTT assay2001Journal of natural products, Mar, Volume: 64, Issue:3
Three new phenolic compounds from a manipulated plant cell culture, Mirabilis jalapa.
AID492140Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay2010Journal of natural products, Jul-23, Volume: 73, Issue:7
An efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds.
AID70654Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID387152Inhibition of xanthine oxidase assessed as decrease of uric acid generation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID1204996Inhibition of Saccharomyces cerevisiae alpha-glucosidase type 1 assessed as 4-nitrophenol cleavage product by high-resolution biochromatogram2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Dual high-resolution α-glucosidase and radical scavenging profiling combined with HPLC-HRMS-SPE-NMR for identification of minor and major constituents directly from the crude extract of Pueraria lobata.
AID366290Cytotoxicity against MDCK cells assessed as maximal non-cytotoxic concentration by MTT assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1082305Antifeedant activity against fourth instar larval stage of Spodoptera litura on fresh cabbage leaves2011Journal of agricultural and food chemistry, Jun-08, Volume: 59, Issue:11
Secondary metabolites from Glycine soja and their growth inhibitory effect against Spodoptera litura.
AID499826Estrogenic activity in human MCF7 cells assessed as increase of estradiol-induced cell proliferation at 10 uM after 48 hrs by clonogenic assay relative to control2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID1074430Inhibition of transthyretin V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of sodium acetate-mediated aggregation preincubated for 30 mins followed by sodium acetate addition measured after 96 hrs by thioflavin T assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Crystal structures of human transthyretin complexed with glabridin.
AID1651899Cytotoxicity against human insulin resistant HepG2 cells assessed as cell viability at 10 uM by CCK8 assay relative to control
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID318607Cytotoxicity against human BXPC3 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID439367Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 5 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1222388Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID265291Increase in ALP activity in mouse primary osteoblasts at 1 uM relative to control2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Osteoblast differentiation stimulating activity of biflavonoids from Cephalotaxus koreana.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1764425Binding affinity to pig pancreatic lipase type 2 assessed as Stern-Volmer quenching constant at 37 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID1447203Potency index, ratio of acarbose IC50 to compound IC50 for alpha glucosidase (unknown origin)2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID736345Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 25 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID318605Cytotoxicity against human KM20L2 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID70660Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID503236Activity of Streptomyces antibioticus OleD P67T mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID318608Cytotoxicity against human MCF7 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID70199Binding affinity against human estrogen receptor alpha in competitive binding assay2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID235514Selectivity was determined as ratio of IC50 against human ER alpha to that of human ER beta2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID1254157Inhibition of human recombinant carbonic anhydrase 4 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1764424Binding affinity to pig pancreatic lipase type 2 assessed as Stern-Volmer quenching constant at 32 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID387151Inhibition of xanthine oxidase assessed as decrease of superoxide generation2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
ortho-dihydroxyisoflavone derivatives from aged Doenjang (Korean fermented soypaste) and its radical scavenging activity.
AID596672Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID400607Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID402364Activity at human estrogen receptor expressed in transgenic Arabidopsis plant at 50 uM by pER8-GFP reporter assay2005Journal of natural products, Jul, Volume: 68, Issue:7
The transgenic Arabidopsis plant system, pER8-GFP, as a powerful tool in searching for natural product estrogen-agonists/antagonists.
AID503238Activity of Streptomyces antibioticus OleD A242V mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID1656434Inhibition of Escherichia coli beta-glucuronidase2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID616299Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID1065094Induction of osteogenic activity in human MSC assessed as cell differentiation after 14 days by alizarin red staining-based spectrometry relative to vehicle-treated control2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.
AID1428454Antibacterial activity against Staphylococcus aureus NCTC 8325-4 by EUCAST method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Termisoflavones A-C, Isoflavonoid Glycosides from Termite-Associated Streptomyces sp. RB1.
AID313354Cytotoxicity against human PANC1 cells in nutrient deprived medium after 24 hrs2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition.
AID1651898Inhibition of alpha-Glucosidase (unknown origin) at 10 uM using pNPG as substrate incubated for 30 mins relative to control
AID503237Activity of Streptomyces antibioticus OleD S123F mutant assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID457086Antioxidant activity assessed as superoxide radical scavenging activity after 2 mins by NBT reduction assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors.
AID84190Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 3 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID404183Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID690145Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID406996Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 40 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1764439Non-competitive inhibition of pig pancreatic lipase type 2 using varying concentrations of p-nitrophenyl butyrate as substrate measured every 1 min for 30 mins by Lineweaver-Burk plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID472108Antiproliferative activity against estrogen receptor expressing human MCF7 cells2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Isoflavones with unusually modified B-rings and their evaluation as antiproliferative agents.
AID1281903Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 1 to 100 uM after 72 hrs by propidium iodide staining-based flow cytometry (Rvb = 22.7%)2016European journal of medicinal chemistry, Apr-13, Volume: 112Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
AID87108Suppression of Hamster ethanol intake by 0.07 mmol o.d. i.p.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID366289Selectivity index, ratio of CC50 to MDCK cells to IC50 to Influenza A Jinan/15/90 H3N2 virus2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1216367Activity of human recombinant UGT1A9 at 100 uM2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Glucuronidation of the red clover isoflavone irilone by liver microsomes from different species and human UDP-glucuronosyltransferases.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID1222395Activation of human recombinant UGT1A1 expressed in HEK293 cells assessed as increase in estradiol 3-glucuronidation by LC-MS/MS method relative to untreated control2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID681379TP_TRANSPORTER: inhibition of EGCG in MRP1-expressing MDCKII cells2003Biochemical and biophysical research communications, Oct-10, Volume: 310, Issue:1
Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
AID439372Agonist activity at human PPARalpha expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 40 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1764431Binding affinity to pig pancreatic lipase type 2 assessed as bathochromic shift of maximum fluorescence intensity at 37 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID745311Inhibition of Helicobacter pylori ATCC 43504 urease-mediated ammonia production preincubated for 1.5 hrs by indophenol method2013European journal of medicinal chemistry, May, Volume: 63Synthesis, structure-activity relationship analysis and kinetics study of reductive derivatives of flavonoids as Helicobacter pylori urease inhibitors.
AID1764436Binding affinity to pig pancreatic lipase type 2 assessed as binding constant at 32 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID1065107Induction of osteogenic activity in human MSC assessed as cell differentiation at 1 uM after 14 days by alizarin red staining-based spectrometry relative to vehicle-treated control2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.
AID1764427Binding affinity to pig pancreatic lipase type 2 assessed as decrease in fluorescence intensity at 32 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID334634Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs by Ames assay in presence of Ames S-9 fraction
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID736341Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 50 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID84343Accumulation of 5 HIAL in isolated Hamster Liver Mitochondria at 0.3 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID1127149Binding affinity to ERbeta (unknown origin) relative to estradiol2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor.
AID84346Accumulation of 5 HIAL in isolated Hamster Liver Mitochondria at 9 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID1719055Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced NO-production at 20 uM after 24 hrs by Griess reagent based assay relative to control2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Synthesis of novel isoflavone/benzo-δ-sultam hybrids as potential anti-inflammatory drugs.
AID366284Inhibition of Influenza A Jinan/15/90 H3N2 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID499831Estrogenic activity in human MCF7 cells assessed as increase of ER-mediated PR expression at 10 uM by RT-PCR analysis in presence of estradiol relative to control2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID404182Cytotoxicity against human A549 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1447216Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.00781 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID84189Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 0.9 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID1764430Binding affinity to pig pancreatic lipase type 2 assessed as bathochromic shift of maximum fluorescence intensity at 32 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID1428453Antibacterial activity against Escherichia coli DH10B by EUCAST method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Termisoflavones A-C, Isoflavonoid Glycosides from Termite-Associated Streptomyces sp. RB1.
AID749998Binding affinity to recombinant paraoxonase-1 (unknown origin) expressed in Escherichia coli2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study.
AID169069In vivo anti-estrogenic activity using an immature rat uterine weight assay.2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
AID1254159Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID756490Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Inhibitory constituents of the heartwood of Dalbergia odorifera on nitric oxide production in RAW 264.7 macrophages.
AID1764437Binding affinity to pig pancreatic lipase type 2 assessed as binding constant at 37 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID681204TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 100 uM, Daidzein: 50 uM) in BCRP-expressing MCF-7 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID596670Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID318611Cytotoxicity against human DU145 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID1216368Activity of human recombinant UGT1A10 at 100 uM2011Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4
Glucuronidation of the red clover isoflavone irilone by liver microsomes from different species and human UDP-glucuronosyltransferases.
AID1764432Binding affinity to pig pancreatic lipase type 2 assessed as quenching rate constant at 27 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID341733Inhibition of hamster liver ALDH22008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase.
AID1281896Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Apr-13, Volume: 112Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
AID503235Activity at Streptomyces antibioticus wild-type OleD assessed as as rate of glucoside formation measured as nanomoles of product formed per minute per mg of enzyme2007Nature chemical biology, Oct, Volume: 3, Issue:10
Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution.
AID499829Estrogenic activity in human MCF7 cells assessed as increase of ER-mediated PR expression at 10 uM by RT-PCR analysis relative to control2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID241876Binding affinity for human Estrogen receptor Alpha; NC= Nonconvergence with an IC50>1 mM2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID70335Inhibition of binding of 17 beta-estradiol to human Estrogen receptor alpha2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID318609Cytotoxicity against human SF268 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID1744553Permeability constant, logPe of compound incubated for 2 to 30 hrs by PAMPA assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33A role of flavonoids in cytochrome c-cardiolipin interactions.
AID1855804Displacement of EL red from human full-length ER-beta expressed in baculovirus expression system incubated for 2 hrs by fluorescence polarization assay2022European journal of medicinal chemistry, Nov-05, Volume: 241An overview on Estrogen receptors signaling and its ligands in breast cancer.
AID499815Estrogenic activity at ER in human MCF7 cells assessed as increase of estradiol-induced transcriptional activity at 1 uM by luciferase reporter gene assay relative to estradiol2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
AID1447217Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.00391 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1719052Cytotoxicity against mouse BV2 cells assessed as cell viability at 20 uM after 24 hrs by XTT assay relative to control2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Synthesis of novel isoflavone/benzo-δ-sultam hybrids as potential anti-inflammatory drugs.
AID402363Activity at human estrogen receptor expressed in transgenic Arabidopsis plant at 5 uM by pER8-GFP reporter assay2005Journal of natural products, Jul, Volume: 68, Issue:7
The transgenic Arabidopsis plant system, pER8-GFP, as a powerful tool in searching for natural product estrogen-agonists/antagonists.
AID1719053Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability at 20 uM after 24 hrs by XTT assay2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Synthesis of novel isoflavone/benzo-δ-sultam hybrids as potential anti-inflammatory drugs.
AID30974Evaluated for time required to reach maximum concentration in plasma2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID472109Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Isoflavones with unusually modified B-rings and their evaluation as antiproliferative agents.
AID1281897Cytotoxicity against human LO2 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Apr-13, Volume: 112Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
AID1764429Binding affinity to pig pancreatic lipase type 2 assessed as bathochromic shift of maximum fluorescence intensity at 27 degC measured after 1 min by fluorescence spectral analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID404184Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID681190TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation (Mitoxantrone: 20 uM, Daidzein: 50 uM) in BCRP-expressing NCI-H460 cells2004Molecular pharmacology, May, Volume: 65, Issue:5
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
AID616386Antioxidant activity assessed DPPH scavenging activity at 500 uM2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID1764433Binding affinity to pig pancreatic lipase type 2 assessed as quenching rate constant at 32 degC measured after 1 min by Stern-Volmer plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID11154Evaluated for Pharmacokinetic property: Area under the curve2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID34047Inhibition of hamster liver aldehyde dehydrogenase ALDH-22001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Synthesis of potential antidipsotropic isoflavones: inhibitors of the mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway.
AID456183Inhibition of reduced carboxymethylated kappa-casein fibril formation at 50 ug/mL measured every 5 mins after 1000 mins by thioflavin T staining-based binding assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
AID1254156Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
AID84345Accumulation of 5 HIAL in isolated Hamster Liver Mitochondria at 3 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID1633148Inhibition of chymotrypsin-like activity of purified human erythrocyte 20S proteasome assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 10 mins and measured by fluorescence based method2019European journal of medicinal chemistry, Apr-01, Volume: 167Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system.
AID1764438Competitive inhibition of pig pancreatic lipase type 2 using varying concentrations of p-nitrophenyl butyrate as substrate measured every 1 min for 30 mins by Lineweaver-Burk plot analysis2021Journal of natural products, 03-26, Volume: 84, Issue:3
Natural Isoflavones and Semisynthetic Derivatives as Pancreatic Lipase Inhibitors.
AID1207646Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID84188Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 0.3 uM.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
AID244129Selectivity for Estrogen receptors alpha and beta2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
AID1364658Inhibition of human 17beta-HSD2 expressed in HEK293 cell lysates assessed as residual enzyme activity at 40 uM incubated for 10 mins using [2,4,6,7-3H]-estradiol and NAD+ by scintillation counting method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
AID356892Displacement of [3H]estradiol from human recombinant ERalpha2002Journal of natural products, Dec, Volume: 65, Issue:12
Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
AID429118Antagonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as inhibition of Dex-induced luciferase activity by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.
AID334635Toxicity in Salmonella Typhimurium T98 at 300 ug/plate after 72 hrs by Ames assay in presence of Ames S-9 fraction
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1800156IC50 Assay from Article 10.1111/cbdd.12157: \\In vitro study of isoflavones and isoflavans as potent inhibitors of human 12- and 15-lipoxygenases.\\2013Chemical biology & drug design, Sep, Volume: 82, Issue:3
In vitro study of isoflavones and isoflavans as potent inhibitors of human 12- and 15-lipoxygenases.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID493017Wombat Data for BeliefDocking2004Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6
Estrogen receptor ligands. Part 1: The discovery of flavanoids with subtype selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,815)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (0.88)18.7374
1990's203 (11.18)18.2507
2000's755 (41.60)29.6817
2010's705 (38.84)24.3611
2020's136 (7.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.14 (24.57)
Research Supply Index7.61 (2.92)
Research Growth Index5.88 (4.65)
Search Engine Demand Index87.22 (26.88)
Search Engine Supply Index2.30 (0.95)

This Compound (47.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials136 (7.21%)5.53%
Reviews66 (3.50%)6.00%
Case Studies1 (0.05%)4.05%
Observational0 (0.00%)0.25%
Other1,682 (89.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blind Randomized Controlled Trial on Whole Soy and Daidzein Supplementation on Reduction of Blood Pressure in Prehypertensive Postmenopausal Chinese Women [NCT01270737]270 participants (Anticipated)Interventional2011-03-31Not yet recruiting
The Effect of Increased Soy Protein Intake on Bone Metabolism [NCT00661856]203 participants (Actual)Interventional2001-01-31Completed
A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy [NCT00669656]Phase 243 participants (Actual)Interventional2008-07-06Completed
The Study of the Effects of Soy Isoflavones on the Metabolism of Glucose and Lipids in Postmenopausal Chinese Women With Impaired Glucose Regulation [NCT00951912]165 participants (Actual)Interventional2009-08-31Completed
The Effects of Red Clover Treatment on Bone Tissue Regulation in Postmenopausal Osteopenia. [NCT02174666]85 participants (Actual)Interventional2014-06-30Completed
Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women [NCT01556737]72 participants (Actual)Interventional2011-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00951912 (15) [back to overview]Percentage Change in 120-minutes Postload Plasma Glucose
NCT00951912 (15) [back to overview]Percentage Change in AUC of Glucose
NCT00951912 (15) [back to overview]Percentage Change in Fasting Plasma Glucose
NCT00951912 (15) [back to overview]Percentage Change in Fasting Plasma Insulin
NCT00951912 (15) [back to overview]Percentage Change in HbA1C
NCT00951912 (15) [back to overview]Percentage Change in High Density Lipoprotein Cholesterol
NCT00951912 (15) [back to overview]Percentage Change in HOMA-IR
NCT00951912 (15) [back to overview]Percentage Change in Low Density Lipoprotein Cholesterol
NCT00951912 (15) [back to overview]Percentage Change in QUICKI
NCT00951912 (15) [back to overview]Percentage Change in Total Cholesterol
NCT00951912 (15) [back to overview]Percentage Change in Triglyceride
NCT00951912 (15) [back to overview]Total Energy Intake at Follow-up
NCT00951912 (15) [back to overview]Total Urinary Isoflavones
NCT00951912 (15) [back to overview]Urinary Daidzein
NCT00951912 (15) [back to overview]Urinary Genistein

Percentage Change in 120-minutes Postload Plasma Glucose

(6th month value-baseline value)/baseline*100% (NCT00951912)
Timeframe: Baseline, 6 months

Interventionpercentage of change (Mean)
Placebo Group-4.90
Daidzein Group-3.13
Geinstein Group-5.59

[back to top]

Percentage Change in AUC of Glucose

values were from 75g glucose oral glucose tolerance test and caculated as (6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

Interventionpercentage of change (Mean)
Placebo Group-6.23
Daidzein Group-3.27
Geinstein Group-5.24

[back to top]

Percentage Change in Fasting Plasma Glucose

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline,6 months

Interventionpercentage of change (Mean)
Placebo Group-1.80
Daidzein Group-1.00
Geinstein Group-4.89

[back to top]

Percentage Change in Fasting Plasma Insulin

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

Interventionpercentage of change (Mean)
Placebo Group25.27
Daidzein Group21.41
Geinstein Group6.06

[back to top]

Percentage Change in HbA1C

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

Interventionpercentage of change (Mean)
Placebo Group-1.38
Daidzein Group-1.37
Geinstein Group-1.30

[back to top]

Percentage Change in High Density Lipoprotein Cholesterol

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group3.18
Daidzein Group1.36
Geinstein Group2.15

[back to top]

Percentage Change in HOMA-IR

HOMA-IR was calculated with the homeostasis model assessment for insulin resistance,and it is caculated as the following equation: HOMA-IR=FIns×FG/22.5, where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group22.83
Daidzein Group21.60
Geinstein Group-0.22

[back to top]

Percentage Change in Low Density Lipoprotein Cholesterol

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group1.08
Daidzein Group-0.93
Geinstein Group1.86

[back to top]

Percentage Change in QUICKI

"QUICKI is the abbreviation of Quantitative Insulin Sensitivity Check Index,and it is a marker to evaluate insulin sensitivity in HOMA model.It is calculated by using the following equation: 1/(logFIns +logFG),where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter.~The percentage change was caculated as (6th month value-baseline value)/baseline value*100%" (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group2.32
Daidzein Group0.18
Geinstein Group6.29

[back to top]

Percentage Change in Total Cholesterol

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group2.85
Daidzein Group-0.59
Geinstein Group-0.64

[back to top]

Percentage Change in Triglyceride

(6th month value-baseline value)/baseline value*100% (NCT00951912)
Timeframe: Baseline, 6 months

InterventionPercentage of change (Mean)
Placebo Group5.93
Daidzein Group3.43
Geinstein Group-1.56

[back to top]

Total Energy Intake at Follow-up

The energy intake was evaluated by 3 days dietary records. (NCT00951912)
Timeframe: an average of the 24 weeks follow-up period which were evalutated on baseline,12 week and 24 week.

Interventionkcal (Mean)
Placebo Group1575
Daidzein Group1473
Geinstein Group1579

[back to top]

Total Urinary Isoflavones

(NCT00951912)
Timeframe: 3 months

Interventionug/ml (Geometric Mean)
Placebo Group8.538
Daidzein Group25.818
Geinstein Group15.467

[back to top]

Urinary Daidzein

Urinary daidzein excretion (NCT00951912)
Timeframe: 3 months

Interventionug/ml (Geometric Mean)
Placebo Group3.34
Daidzein Group11.80
Geinstein Group3.73

[back to top]

Urinary Genistein

Urinary genistein excretion (NCT00951912)
Timeframe: 3 months

Interventionug/ml (Geometric Mean)
Placebo Group1.32
Daidzein Group1.89
Geinstein Group6.54

[back to top]